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The hERG potassium channel, which mediates the rapid delayed rectifier current IKr, is critical 
in determining the duration of cardiac action potentials (APs) and therefore the length of the 
QT interval. Within the last 15 years, gain-of-function hERG mutations have been identified 
clinically and these have been shown to abbreviate repolarisation, causing variant 1 of the 
short QT syndrome (SQT1), with symptoms including atrial fibrillation, syncope and sudden 
cardiac death. Recently, two new mutations have been associated with SQT1. The f irst of 
these, I560T, was published alongside electrophysiological data which showed the mutation 
to modestly affect hERG inactivation, but a more detailed characterisation of channel 
properties has not been undertaken. The second mutation, S631A, has been studied in vitro 
since 1996, when it was shown to cause signification attenuation of inactivation across 
physiological voltages.  
Now that both mutations have been identified clinically, this study aimed to characterise fully 
the kinetics of I560T-hERG; to investigate the effect of both mutations on hERG current (IhERG) 
during physiological APs; and to evaluate mutant channels’ affinity for anti-arrhythmic drugs. 
Using whole-cell patch clamp recordings of wildtype and mutant IhERG in HEK cells, this work 
shows the I560T mutation to increase IhERG density and attenuate channel inactivation whilst 
also affecting wider channel properties. These changes lead to augmentation of IhERG during 
APs and can be expected to increase susceptibility to arrhythmia. Similarly, the attenuation of 
inactivation caused by the S631A mutation was shown to shift IhERG timing to significantly 
earlier during repolarisation which can be predicted clinically to abbreviate repolarisation and 
increase propensity for arrhythmia. Application of quinidine to cells expressing I560T or 
S631A-hERG showed that the channels’ affinity for the drug was only modestly affected by 
the mutation, whilst sotalol also retained effectiveness in blocking I560T-hERG, thus 
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 Chapter 1     Introduction 
1.1 Cardiac function 
Normal cardiac function is dependent upon the propagation of electrical impulses from 
pacemaking cells in the sinoatrial node, through the specialized conduction system and 
working myocardium. This co-ordinated activity triggers orderly contraction of the atria and 
ventricles, pushing deoxygenated blood to the pulmonary circulatory system and oxygenated 
blood to the remaining muscles and organs as required (Nerbonne and Kass, 2005, Hoshi 
and Armstrong, 2013). Excitation and contraction is followed by an electrical refractory 
period, which allows the relaxed heart to fill with blood while re-establishing a negative 
membrane potential within cells (Courneya and Parker, 2011). 
The period required for myocardial depolarisation and repolarisation is termed the action 
potential duration (APD) and can be measured noninvasively via the electrocardiogram 
(ECG). As shown schematically in Figure 1, the surface ECG reflects the action potentials 
(APs) triggered by cardiac excitation, with atrial (PR interval) and ventricular (QT interval) 
APs each showing a distinct morphology. The diversity of AP waveforms across different 
tissues are a consequence of the changes in ion channel expression between the cell types 
(Nerbonne and Kass, 2005). For example, Kir2.1 (which contributes to the inwardly rectifying 
K+ current, IK1) is expressed more highly in the ventricles, Kir3.1 (which mediates the acetyl-
choline activated K+ current, IK,Ach) is expressed more highly in the atria and hERG (Ikr) 
expression is similar across all cardiac tissues (Schram et al., 2002, Gaborit et al., 2007). 
Variations in expression of a number of other channel types including ultrarapid delayed 
rectifiers (Kv1.5; IKur) voltage-dependent calcium channels (Cav1.2; ICa,L) and G-protein-gated 
K+ channels (Kir3.4, IK,Ach) all combine to produce the described AP alterations (Gaborit et 
al., 2007). Furthermore, as show schematically in Figure 2, APD is also dependent upon the 
activation and inactivation profiles of different channel types instigated by the change in 





The human ventricular action potential (Figure 2) is typically split into five separate phases 
with each representing a distinct pattern of ion permeability (Huang et al., 2017). In the atrial 
and ventricular myocardium, during phase 4 the membrane is held at a resting potential of ~-
80mV by inwardly rectifying K+ current (IK1), with cells depolarising once the incoming wave 
of electrical excitation drives the membrane potential past the AP threshold of ~-60mV. At 
this voltage an influx of sodium ions via fast sodium channel current (INa) drives the 
membrane potential to +60mV (phase 0) before fast inactivation of the channel and 
activation of Ito,fast  (transient outward current) forms the AP notch (phase 1). Subsequently 
phase 2, the plateau phase, begins as the membrane potential is kept relatively constant by 
a balance of L-type Ca current (ICa-L) and composite delayed rectifier K+ current, which is 
comprised of the rapid and slow delayed rectifiers (IKr and IKs) (Charpentier et al., 2010). IKr 
increasingly contributes to the membrane potential and eventually begins cellular 
repolarisation (phase 3) before it is deactivated by the negative resting potential and IK1 
 
Figure 1: Human action potential waveforms. The different regions of the human heart annotated with 
the AP waveform seen in specific tissue types. Waveforms are aligned with an ECG trace for 
identification of different intervals, with the QT interval clearly aligning with the ventricular action 
potential. Modified from Bartos et al. (2015).  RA and LA denote right and left atria respectively, whilst 
RV and LV denote right and left ventricles. SAN and AVN denote the sinoatrial and atrioventricular 





again becomes the dominant current. In atrial, but not ventricular cells in the human heart an 
additional current, the ultrarapid delayed rectifier (IKur) also contributes to repolarization 
(Figure 2; Moreno et al, 2012). 
1.2 Role of hERG  
1.2.1 Characterisation of Ikr and hERG 
Understanding contribution of IKr to cardiac action potentials initially began when seminal 
work by Noble and Tsien (1969) revealed two distinct components to cardiac delayed 
outward K+ current (IK) following depolarisation. These two components, then termed Ix1 and 
Ix2 due to the possible conductance of other ions in addition to potassium, were 
distinguishable from one another due to the much more rapid activation and inward 
rectification of Ix1 (Noble and Tsien, 1969). Further classification of these two components, 
 
Figure 2: Human cardiac currents. Ionic currents involved in the different phases of atrial and 





however, was made possible in 1990 through use of the novel pharmacological compound 
E-4031 (Sanguinetti and Jurkiewicz, 1990).  
E-4031 was shown to prolong the action potential duration of guinea pig ventricular 
myocytes by reducing IK and inhibiting only the rapidly activating Ix1, then termed IKr (rapidly 
activating delayed rectifier current) and hence distinguish it pharmacologically from the 
slowly activating Ix2 (redefined as IKs) (Sanguinetti and Jurkiewicz, 1990). Consequently, E-
4031 was used to show the drug-sensitive IKr as a current with inward rectification across the 
positive voltage range and with a maximal current which saturated at ~10mV. This was in 
contrast to IKs which continued to increase across the positive voltage range. Differences in 
the voltage dependence of activation and K+ selectivity were also shown (Sanguinetti and 
Jurkiewicz, 1990).   
Subsequent to this work, mutations in the recently discovered K+ channel gene, hERG 
(human Ether-à-go-go-Related Gene; alternative nomenclature KCNH2), were also shown to 
be linked to prolongation of the QT interval and the hERG protein was shown to be highly 
expressed in the heart (Warmke and Ganetzky, 1994, Curran et al., 1995). Consequently, 
the channel was experimentally expressed in oocytes in order to define its physiological role 
(Sanguinetti et al., 1995, Trudeau et al., 1995). This work showed that hERG current (IhERG) 
to reach its peak outward current at a voltage of ~10mV and to decline at positive voltages, 
properties similar to those previously reported for IKr (Sanguinetti and Jurkiewicz, 1990, 
Sanguinetti et al., 1995, Trudeau et al., 1995). Furthermore, this rectification was also shown 
to be due to rapid inactivation, as previously suggested for the rectification of IKr (Shibasaki, 
1987); the dual components of deactivation identified matched those reported for IKr (Yang et 
al., 1994); and modulation of current by extracellular K+ was similar to that of IKr (Sanguinetti 
and Jurkiewicz, 1992). Many of these properties are distinct from any other characterised 
cardiac currents, and so the study provided ample evidence that channels mediating IKr 





Despite this evidence, the kinetics of the IhERG did not match those of IKr exactly, and so the 
identification of an alternate hERG transcript specifically expressed in the heart was of great 
interest to the field (Lees-Miller et al., 1997, London et al., 1997). The two papers, published 
simultaneously from different laboratories, identified mouse ERG (mERG) 1a and 1b as 
alternate transcripts. Whilst mERG 1a shares >99% identity with that of the protein 
previously characterised as hERG, mERG 1b was shown to have an N-terminus ~340bp 
shorter and capped with a unique sequence of 36 amino acids (Lees-Miller et al., 1997, 
London et al., 1997). Subsequently, mERG 1b was shown to co-assemble with mERG 1a in 
oocytes and its more rapid deactivation (compared with that of mERG 1a) caused the 
resulting heteromer to possess kinetics which more closely resembled that of IKr (London et 
al., 1997). Although initial studies suggested that ERG 1b proteins were not expressed in 
cardiac tissues (Pond et al., 2000, Finley et al., 2002), improvements in antibodies in 
subsequent years demonstrated the expression of both isoforms in rat, canine and human 
hearts (Jones et al., 2004) and more recent work on human induced pluripotent stem cell 
(iPSC) derived cardiomyocytes provides evidence that currents mediating native IKr are 
sensitive to knockdown of hERG1b (Jones et al., 2014), suggestive that human IKr involves 
hERG 1b in addition to hERG 1a. 
The two hERG isoforms preferentially form heteromers, with direct N-termini interactions 
masking an ER retention signal present in hERG 1b which prevents homomeric 1b channels 
from forming in humans (Phartiyal et al., 2007, Phartiyal et al., 2008, McNally et al., 2017). 
These make up the alpha, pore-forming subunits of tetrameric hERG channels, with each 
monomer consisting of six transmembrane segments (S1-S6) (Vandenberg et al., 2012, 
Wang and MacKinnon, 2017). As shown in Figure 3A and 3B, S5 and S6 from each 
monomer contribute to the pore-forming domain of the channel, with the amino acid loop 
which connects them containing the pore helix and selectivity filter. The cytoplasmic S4-5 
linker connects the voltage-sensing domain (VSD; comprised of S1-S4) to the pore-forming 





coupled with the gating of both activation and inactivation (Wang and MacKinnon, 2017, 
Helliwell et al., 2018). Each monomer also has a cytoplasmic C- and N-terminus, the latter of 
which contains the PAS domain (in hERG 1a only) which characterises the ERG subfamily 
of voltage-gated potassium channels (Vandenberg et al., 2012).  
In addition to the major pore-forming subunit, potential roles for the KCNE1 (MinK) and 
KCNE2 (MiRP1; encoded by KCNE1 and KCNE2 respectively) as β-subunits in IKr have 
been suggested in the literature, but the exact nature of the relationship is still debated 
(Anantharam and Abbott, 2005, Hancox et al., 2008, Vandenberg et al., 2012). KCNE1 is 
well documented to associate with KCNQ1 α-subunits to mediate the IKs current (Barhanin et 
al., 1996, Sanguinetti et al., 1996), but it’s co-expression with hERG has also been shown to 
 
 
Figure 3: Structure and gating of hERG channels. (A) Simplified representation of opposing hERG 
monomers with N-terminus (blue), VSD (green), pore-forming domain (yellow) and C-terminus 
(orange) indicated (adapted from Vandenberg et al. (2012)). (B) hERG membrane domain based on 
the recent cryo-EM structure (Wang and MacKinnon, 2017), with voltage sensor (VS), selectivity filter 
(SF) and pore helix highlighted alongside selected residues. Provided by Dr Christopher Dempsey 






increase current density but without altering gating kinetics, and mutations to KCNE1 reduce 
this effect (McDonald et al., 1997, Bianchi et al., 1999). Importantly, the A8V mutation in 
KCNE1 has been shown to cause arrhythmia and a prolonged QT interval in vivo, whilst co-
expression of A8V- KCNE1 and KCNQ1 in vitro caused little change to current properties 
and co-expression of A8V- KCNE1 and hERG significantly reduced hERG current density 
(Ohno et al., 2007). The study therefore, demonstrates a significant effect on hERG can be 
caused directly by the KCNE1 protein (Ohno et al., 2007). In addition to this, imaging work 
has shown hERG to be more likely to associate with KCNE1 than KCNE2 in recombinant 
channel expression experiments (Um and McDonald, 2007). 
In contrast to KCNE1, KCNE2 has been shown to decrease hERG current density and 
increase the rate of deactivation, whilst also possibly having an effect on the voltage 
dependence of activation (Mazhari et al., 2001, Weerapura et al., 2002b). Further work has 
also shown KCNE2 to facilitate hERG degradation, which may contribute to the alterations 
seen in current density but cannot account for changes in kinetic properties (Zhang et al., 
2012); and mutations to KCNE2 to affect hERG block by some pharmacological agents 
(Abbott et al., 1999, Sesti et al., 2000). Although such interactions are clearly evident in 
expression systems, in vivo KCNE2 has been shown to only be express at very low levels 
outside the conduction system and so it is unlikely that such interactions are critical for 
hERG function (Lundquist et al., 2005, Sanguinetti and Tristani-Firouzi, 2006). Overall, 
current literature suggests ability of KCNE1 and KCNE2 to interact with hERG in expression 
systems, but more work is required regarding their roles in the native current. The hERG 1a 
protein is central to the current, with hERG1b potentially also playing a role. 
 
1.2.2 Rapid inactivation 
The predominant contribution of IKr to repolarization during the late phase of the ventricular 
action potential is a result of hERG’s unusual voltage-dependent activation and inactivation 





voltage-gated potassium channels (Kv channels) can transition between the closed, 
activated and inactivated states (Figure 3C), the speed at which hERG transitions between 
these are part of what makes it unique (Spector et al., 1996, Cheng and Claydon, 2012). 
Although activation time-course of hERG is fast in comparison that of IKs, it is slow when 
compared to its own inactivation. Macroscopic IhERG activation occurs over hundreds of 
milliseconds in hERG, whereas transitioning from the open to the inactivated state is much 
more rapid, taking under 10ms. Consequently, at more positive voltages the channel is 
instantaneously inactivated, leading to the rectification of current described above. 
(Charpentier et al., 2010, Cheng and Claydon, 2012).  
This C-type inactivation was first described in 1996 in work by both Schonherr et al. and 
Smith et al. In the first of these, the K+ channel blocker tetraethylammonium (TEA) was 
applied both intra- and extracellularly and shown to only affect rate of inactivation when 
applied to the extracellular surface, indicative of C-type inactivation (Smith et al., 1996). This 
was further supported when the S631A mutation, corresponding to a residue which is critical 
for C-type inactivation in other Kv channels (Hoshi et al., 1991), was induced into hERG and  
shown to remove this inactivation under the experimental conditions (Schonherr and 
Heinemann, 1996).  
Typical Kv channels display voltage-dependent inactivation with a significantly longer time-
course and although the exact mechanisms underlying the rapidity of hERG inactivation are 
not clear, a number of studies have helped identify differences between S6 and the 
selectivity filter of hERG compared with other channels with shared homology. Using a 
chimera of the non-inactivating mEAG channel and hERG, it has been shown that mutation 
of a small S6-Pore region (residues 613-650) was able to confer rapid, voltage-dependent 
inactivation (Herzberg et al., 1998) to mEAG. In addition to this, five key residues shown as 
pivotal for stabilising hydrogen bonds in the selectivity filter of the well-characterised 
bacterial Kv channel KcsA, are not conserved in hERG, possibly enabling it to change state 





recently has been shown to be uniquely positioned when compared to both EAG and KcsA 
in a cryo-electron microscopy structure (Wang and MacKinnon, 2017), further supporting a 
distinctive hERG pore structure which may contribute to its rapid collapse. 
 
1.2.3 Experimental demonstration of hERG properties 
The properties of IhERG can be demonstrated experimentally using whole-cell patch clamp 
and conventional ‘step’ voltage protocols to control the membrane potential, as can be seen 
in Figure 4A. Following depolarization to +20mV, the relatively slow activation occurs and 
current begins to flow but is limited in size by rapid inactivation (portion of trace shown in 
red). Once the voltage is repolarised to -40mV, inactivation is rapidly removed, resulting in a 
resurgent ‘tail’ current with a rapid increase in current amplitude which then declines as the 
slower deactivation occurs and channels return to their resting state (portion of trace 
coloured in green).  
As shown in Figure 4B, in which a ventricular AP was applied to a hERG-expressing cell 
using whole-cell patch clamp techniques (see Sections 3.2.2.1 and 4.2.1.2), this slow 
activation and rapid, voltage-dependant inactivation mean that during phase 4 hERG 
channels deactivate and phases 0 and 1 see slow activation but rapid inactivation which 
limits current size. During phase 2, further activation occurs and as the plateau begins to 
lower, the decrease in membrane potential removes inactivation. Consequently, phase 3 
sees the highest level of IKr as channels are fully open and inactivation progressively reduces 
as membrane potential falls. In vitro, the fully activated channel has been observed to drive 
membrane repolarisation, forcing the channels back in to the closed state (Hancox et al., 





Additionally, this slow deactivation confers a protective effect against arrhythmias triggered 
by prematurely occurring APs as it leaves a proportion of the channels in the open state 
during the later phases of the AP (Lu et al., 2001, McPate et al., 2009a, Melgari et al., 2014). 
Consequently, as shown in Figure 4C, if a second, overlapping AP occurs, a large transient 
current is passed. This current is limited in duration by rapid inactivation but is large enough 
 
Figure 4: Experimental demonstration of hERG properties. (A)  Typical trace of WT IhERG with 
corresponding voltage protocol. Coloured sections represent IhERG following channel activation in the 
presence of rapid inactivation (red), and slow hERG deactivation following the removal of inactivation 
(green). (B)  Typical profile of WT IhERG (shown in black) during a ventricular action potential (shown 
in grey). Numerical annotations represent the phase of the AP.  For (A, B) IhERG recordings were 
made by myself from HEK293 cells expressing hERG using whole-cell patch clamp at 37oC. All 
presented data is in line with widely published data (Hancox et al., 1998a, Lu et al., 2001, McPate et 
al., 2005, McPate et al., 2009a, Zhang et al., 2011) (C) Effect of premature ventricular AP stimuli on 






supress sodium channel (INa) activation; oppose the premature depolarisation; drive normal 
repolarisation; and prevent the activation of L-type Ca2+ which are associated with further 
arrhythmogenesis (Lu et al., 2001).  
 
1.3 Alterations in QT interval 
1.3.1 The long and short QT syndromes 
The patients in whom Curran et al. (1995) first identified KCNH2 mutations were suffering 
from a prolongation of the QT interval which caused seizures, syncope and aborted sudden 
death, and often had a family history of sudden cardiac death (SCD). This occurs as loss-of-
function mutations reduce hERG’s ability to terminate the plateau phase of the action 
potential and drive repolarisation (Witchel and Hancox, 2000, Sanguinetti and Tristani-
Firouzi, 2006, Charpentier et al., 2010). In addition to KCNH2, mutations in SCN5A and 
KCNQ1, encoding NaV1.5 (INa) and KV7.1 (IKs) respectively have been shown to cause 
LQTS. These three genes contribute to >90% of cases of congenital LQTS, with hERG 
mutations accounting for ~40% of these (Vandenberg et al., 2012). Furthermore, off-target 
pharmacological inhibition of hERG channel current (IhERG) and/or trafficking is also 
responsible for the majority of acquired LQTS incidents (Hancox et al., 2008). LQTS is most 
commonly diagnosed according to the Schwartz criteria, which accounts for family history of 
cardiac symptoms and the patients’ own clinical history in addition to ECG characteristics. A 
rate-corrected QT (QTc) interval of >450ms is seen as an LQTS risk factor whilst those with 
a QTc of ≥480ms are at the highest risk (Schwartz and Ackerman, 2013, Baskar and Aziz, 
2015). This prolongation of the QT interval can lead to early afterdepolarizations through the 
re-activation of Ca2+ or Na+ channels and cause severe ventricular tachycardia, torsades de 
pointes and syncope or SCD (Yap and Camm, 2003, McPate et al., 2008, Chen et al., 2016).  
Similarly, a reduction in QT interval can cause ventricular or atrial fibrillation, polymorphic 
ventricular tachycardia, syncope and SCD (Maury et al., 2008, Harrell et al., 2015, Chen et 





inward depolarizing causes a decrease in APD and in the effective refractory period which 
can promote a uni-directional block in electrical current, leading to a substrate for re-entrant 
arrhythmia (Bjerregaard et al., 2006, Tse et al., 2017, Hancox et al., 2018). Current clinical 
guidelines recommend a QTc interval of ≤340ms to be diagnostic of SQTS, although this can 
be expanded to ≤360ms in the presence of a pathogenic mutation; family history of SQTS or 
SCD; or survival of episodes of ventricular tachycardia or fibrillation in the absence of heart 
disease (Priori et al., 2015). The adjustment of these guidelines over time (Ackerman et al., 
2011, Gollob et al., 2011, Priori et al., 2013, Priori et al., 2015) mean that large population 
studies aiming to quantify the prevalence of SQTS have used different reference ranges for 
their research. A very short QTc interval of ≤320ms has been found with a prevalence of 
0.1% (Anttonen et al., 2007, Dhutia et al., 2016), QTc interval of ≤330ms at 0.2% (Dhutia et 
al., 2016) and, most clinically relevant, QTc interval of ≤340ms has been shown to be 
prevalent in 0.05-0.4% of the population (Anttonen et al., 2007, Guerrier et al., 2015), whilst 
a male predominance for the syndrome has been consistently highlighted (Anttonen et al., 
2007, Miyamoto et al., 2012, Guerrier et al., 2015, Dhutia et al., 2016). Despite this 
prevalence of an accelerated QT interval, clinical diagnoses of SQTS remain rare (Mazzanti 
et al., 2017b, Hancox et al., 2018). Increased understanding of the disorder, however, has 
further reaching implications, with knowledge of how variations in ionic conductance 
contribute to arrhythmogenic wavebreak formation; stabilisation of rotors; and post-
repolarisation refractoriness being key for a better understanding of other idiopathic 
arrythmias including atrial and ventricular fibrillation (Cerrone et al., 2006).  
 
1.3.2 Identification of SQTS  
SQTS as a distinct congenital entity is a relatively new disorder with the first discussion in 
the literature occurring within the last twenty years (Gussak et al., 2000). Then an idiopathic 
condition, Gussak et al’s study described three subjects from the same family presenting 





rhythmic abnormalities. A fourth, unrelated patient with syncope and subsequent SCD 
following the identification of a dramatically shortened QT interval was also presented.  
A genetic cause of SQTS was first recognised in 2004 with the clinical identification of 
missense mutations to the KCNH2 gene leading to an asparagine to lysine substitution 
(N588K) in the S5-Pore linker region of the hERG channel protein (Brugada et al., 2004). 
Using TSA201 cells transiently transfected with WT or N588K hERG, the authors showed 
this mutation to disrupt inactivation, resulting in reduced current rectification at positive 
voltages and augmented activation during a ventricular AP which could physiologically 
abbreviate the QT interval (Brugada et al., 2004). Subsequent work further supported these 
findings, showing a positive shift in rectification caused by a ~60mV shift in half-maximal 
inactivation; and IhERG density and timing to be altered during ventricular, atrial and Purkinje 
fibre APs (McPate et al., 2005, McPate et al., 2009a). As the first gene to be directly linked 
with SQTS, mutations to KCNH2 gene make up the genotypic group of SQT1. Subsequently, 
the SQT1 mutation T618I, located within the pore-loop region of the hERG channel, has 
been established as the most commonly occurring SQTS mutation, although the exact 
mechanisms underlying abbreviation of the QT interval remain unclear (Sun et al., 2011, El 
Harchi et al., 2012, Hu et al., 2017, Hancox et al., 2018); and mutations to the N- and C-
termini of hERG channels (E50D and R1135H) have been reported to slow the rate of 
channel deactivation in further SQT1 patients, which could in turn contribute to an 
abbreviation of repolarisation (Itoh et al., 2009, Hu et al., 2017). 
As summarised in Table 1, gain- and loss-of-function mutations which drive repolarisation 
and reduce then QT interval have since been identified across 7 further genes, the most 
recent of which occurred just last year (Thorsen et al., 2017). Whereas most genomic 
analysis of SQTS patients involves the screening of candidate genes, this SQT8-identifying 
work used whole exome sequencing to, for the first time, recognise a mutation in an anion 
transporter with two potential mechanisms of abbreviating repolarisation (reduced 





increase in understanding of SQTS since its relatively recent discovery, this successful use 
of whole exome sequencing contrasted with the knowledge that only ~25% of SQTS 
diagnoses have been successfully genotyped highlights there is still much work to be done 
to fully characterise the disease (Thorsen et al., 2017, Hancox et al., 2018). 
Gene  Effect of mutation  SQTS type  
KCNH2  IKr SQT1 
KCNQ1  IKs SQT2 
KCNJ1  IK1 SQT3 
CACNA1C  IL,Ca SQT4 
CACNB2  IL,Ca SQT5 
CACNA2D1  IL,Ca SQT6 
SCN5A  INa SQT7 
SLC4A3  ICl, pHi SQT8 
Table 1: Genes associated with SQTS. Three potassium channels, 
three calcium channels, a sodium channel and one anion exchanger 
have been shown as the causes of the 8 identified variants of SQTS. 
Adapted from Rudic et al. (2014), Perez Riera et al. (2013), Hancox et 
al. (2018). 
 
1.3.3 Treatment of SQTS 
SQTS patients are at high risk of SCD, with prevalence of cardiac arrest at 4% in the first 
year of life, 1.3% per year between 20 and 40 years, and 41% by 40 years of age (Mazzanti 
et al., 2014). Implantable cardioverter-defibrillators (ICDs) currently offer a reliable 
preventative measure and are consequently commonly used in patients (Schimpf et al., 
2007). Adjunctive or alternative pharmacological agents however are important as ICDs can 
trigger inappropriately due to the large T waves seen in some SQTS patients (Giustetto et 
al., 2011, Mondoly et al., 2016); and ICD implantation can present technical difficulties, 





follow-up study of SQTS patients reported 58% of patients to have complications associated 
with ICDs (Giustetto et al., 2011). In order to increase the likelihood of these therapeutic 
interventions having the desired effects, an understanding of specific SQT1 mechanisms is 
required as hERG mutations have been shown to affect drug binding in varying ways. 
For example, a large number high affinity drugs bind to the inactivated state of hERG much 
more strongly than they bind the open, activated state (McPate et al., 2008, Perrin et al., 
2008), and as a consequence mutations which attenuate hERG inactivation, such as the 
N588K mutation, can reduce the affinity of pharmacological agents. This was demonstrated 
experimentally when N588K was shown to be associated with a 20-fold reduction in affinity 
for the IKr blocking Class III antiarrhythmic drug D-sotalol (Wolpert et al., 2005). Residues 
Y652 and F656 (S6 domain) as well as T623, S624 and V625 (pore helix), have been shown 
as key binding sites for class 1a antiarrhythmics such as disopyramide and quinidine 
(Mitcheson et al., 2000, Helliwell et al., 2018). For these drugs, the perturbing of inactivation 
had little to no effect on hERG blockage while the mutation of key residues caused a 
profound reduction in channel block (Lees-Miller et al., 2000a, Paul et al., 2001, McPate et 
al., 2006). Such findings have been taken into a small clinical trial supporting the 
effectiveness of disopyramide in SQT1 patients with the N588K mutation, and so it is clear 
that in vitro study of KCNH2 mutations can help produce, and potentially predict, more 
optimal treatment for patients (Schimpf et al., 2007). 
1.4 Recently identified SQT1 mutations 
In the last three years, two new mutations have for the first time been found to cause SQT1 
in patients. Firstly in 2015, a novel heterozygous hERG mutation was identified in a 64-year-
old male presenting with palpitations, near syncope, paroxysmal atrial fibrillation and a QT 
interval of 319ms. There was also a family history of SCD. This c.1679T>C missense 
mutation caused an isoleucine to threonine substitution at the highly conserved position 560 
(I560T) in S5 of hERG (Figure 3B) (Harrell et al., 2015). The authors then used whole-cell 





QT interval by modifying the inactivation properties of the channel. Although 
electrophysiological characterisation of voltage-dependence of activation and inactivation of 
the channel was performed, there was no analysis of the time-dependence of activation, 
deactivation, inactivation or the recovery from inactivation; and the reported voltage of half 
maximal inactivation in the WT was positively shifted in comparison with previously reported 
data from this and other laboratories (Vandenberg et al., 2006, Sun et al., 2011, Zhang et al., 
2011, El Harchi et al., 2012). Furthermore, no work has yet been undertaken to establish the 
response of the channel to physiologically relevant AP waveforms and no work has been 
conducted to evaluate any changes in antiarrhythmic drug affinity caused by the mutation. 
Such information may be of particular value both due to the location of the residue relative to 
the pore region that contains the canonical binding site (Mitcheson et al., 2000, Harrell et al., 
2015, Helliwell et al., 2018); and also because the index patient declined ICD implantation 
(Harrell et al., 2015).  
In a separate study, a 6-year-old female is described who was initially screened following the 
sudden death of a cousin aged 17. At the time, she presented with a QTc interval of <320ms 
but she remained asymptomatic until the onset of arrhythmic syncope during exercise at 16 
years of age, at which point she was fitted with an ICD. Most recently, at the age of 18, an 
ECG revealed a QTc interval of 323ms, but she has remained asymptomatic since 
implantation. Next generation sequencing was used and the authors determined the 
heterozygous hERG missense mutation c.1891T>G to be the cause of shortened QTc. This 
mutation leads to a serine to alanine substitution at position 631 (S631A) in the pore region 
of the hERG channel (Figure 3B) (Akdis et al., 2017). The S631A mutation has been 
previously engineered for use in experimental work to aid the understanding of both hERG 
inactivation and drug binding (Schonherr and Heinemann, 1996, Hancox et al., 1998b, Lees-
Miller et al., 2000a, McPate et al., 2008), and consequently there is a strong body of work 
describing the biophysical properties of S631A-hERG. Now that the mutation has been 









It can be seen from the background described that correct ion channel operation is vital for 
maintenance of normal cardiac function and the normal features of hERG activation and 
inactivation are key in the prevention of arrhythmogenesis. Specific point mutations which 
affect the hERG protein that mediates IKr must be characterised to aid clinical responses as 
well as to increase understanding of both SQTS and wider arrhythmia. Following the clinical 
identification of the I560T and S631A mutations, the aims established for my current 
master’s project are to: 
1) Fully characterise the I560T-hERG mutation’s effects on IhERG amplitude and kinetics, 
in order to identify the way in which the change can cause a shortening of the QT 
interval. 
2) Investigate the impact of the I560T mutation on pharmacological properties of hERG 
using clinically relevant antiarrhythmic drugs that inhibit wild-type (WT) IhERG. 
3) Supplement the existing information, generated from conventional voltage clamp, by 
characterising the effect of the S631A mutation on IhERG during AP waveforms and on 






Chapter 2     Materials and methods 
2.1 Mutagenesis 
The hERG channel containing the I560T mutation was generated externally by Mutagenex 
Inc (Suwanee, GA 30024, USA) from a WT construct in modified pcDNA3. DH5α 
Escherichia coli (Invitrogen, Paisley, UK) were then transformed, as previously in this 
laboratory (Zhang et al., 2011), before DNA was purified using an endotoxin-free plasmid 
DNA purification kit (Neumann-Neander-Str., Germany, Macherey-Nagel), and the mutated 
sequence was confirmed through sequencing of the complete open reading frame (Eurofins 
MWG Operon, Ebersberg, Germany). 
S631A-hERG plasmids previously studied in this laboratory were used for all experiments 
(Hancox et al., 1998b, McPate et al., 2008, Melgari et al., 2015). For this, hERG cDNA was 
subcloned into pGW1H expression vectors and the S631A mutation induced using PCR with 
a correcting polymerase (Vent, New England Biolabs). Sequencing was confirmed by LICOR 
technology (Hancox et al., 1998b, Paul et al., 2001). 
 
2.2 Cell culture and transfection 
Human embryonic kidney cells (HEK 293; European Collection of Cell Cultures, Porton 
Down, UK) were used for all work assessing the kinetic properties IhERG (Sections 3.2.1, 3.2.2 
and 4.2.1). As shown in Figure 5, these cells are devoid of a native IhERG, although some 
endogenous current is present. As hERG is expressed well in these cells, IhERG was 
sufficiently large in all experiments that the native current was deemed to not influence the 
data collected, and so in line with previous studies, it was not accounted for during data 
analysis (McPate et al., 2008, Zhang et al., 2011, El Harchi et al., 2012, Du et al., 2014, 
Zhang et al., 2016). HEK cells were incubated at 37°C, 5% CO2, in DMEM containing 
glutamax-1 (DMEM; Gibco, Paisley, UK) and supplemented with 10% fetal bovine serum 





Aldrich, Gillingham, UK), cells were transfected with cDNA plasmids encoding either WT or 
mutant hERG channels using Lipofectamine 2000 (Invitrogen, Paisley, UK). During all WT 
experiments and the majority of I560T experiments, 1µg of cDNA was transfected. During 
studies of IhERG inactivation however (which involve manoeuvres that result in large currents; 
Figure 9), it was seen that I560T IhERG was too large to be accurately recorded when cells 
were transfected with 1µg of cDNA, and consequently only 0.15μg of mutant cDNA was 
used for this protocol. Similarly, due to the attenuation of inactivation and subsequent 
increase in IhERG caused by the S631A mutation (Hancox et al., 1998b, McPate et al., 2008), 
a reduced volume of this cDNA (0.5µg) was also used. CD8-encoding cDNA (0.15μg) was 
additionally transfected into the cells (in pIRES, donated by Dr I Baró, University of Nantes, 
France) to allow detection of successful transfection using Dynabeads® (Invitrogen, Paisley, 
UK), as also seen previously (Zhang et al., 2011, Melgari et al., 2015). 
 
Although these cells were also used for assessing the response of mutant hERG channels to 
pharmacological agents, a line of HEK 293 cells stably expressing WT hERG (donated by Dr 
 
Figure 5: HEK 293 cells do not natively express hERG. (A) Representative trace elicited by the 
protocol in the lower panel, recorded from a HEK 293 which has not undergone transfection. (B) 
Representative trace elicited by the protocol in the lower panel, recorded from a HEK 293 cell which 







































































Craig January, University of Wisconsin) was used in comparative WT studies (Sections 3.2.3 
and 4.2.2). These cells were treated as above, with the addition of 400 μg/mL geneticin 
(G418, Gibco) to the cell culture medium; and passage using enzyme free cell dissociation 
solution (Millipore, Watford, UK) as an alternative to trypsin. All cells were plated onto 
sterilized 13-mm glass coverslips in 40-mm Petri dishes containing their respective medium 
for electrophysical recordings.  
 
2.3 Solutions for electrophysiological recordings 
In keeping with similar studies performed in this lab (Du et al., 2014, Zhang et al., 2016), 
normal Tyrode’s solution containing (in mM): 140 NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10 
Glucose, and 5 HEPES (titrated to pH of 7.45 with NaOH) was superfused over cells at 37°C 
± 1°C. Patch-pipettes, fire-polished to 2.5–4 MΩ, were filled with a dialysis solution 
containing (in mM): 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP, and 10 HEPES (titrated to pH of 
7.2 with KOH). Quinidine powder (Quinidine gluconate salt) and Sotalol (both Sigma-Aldrich, 
Gillingham, UK) were dissolved in Milli-Q water to produce initial stock solutions of 10mM 
and 50mM respectively. These were serially diluted in Milli-Q water to produce a range of 
stock solutions to be stored at -20°C. One the day of use, stock solutions were finally diluted 
in Tyrode’s solution to produce the required concentrations as described in the results. 
 
2.4 Experimental procedure and analysis 
Measurements of IhERG were made through whole-cell patch clamp recording of membrane 
currents using an Axopatch 200A amplifier featuring a 4-pole internal Bessel filter (Axon 
Instruments, Foster City, CA, USA) and a CV201 head stage. Electrode series resistance 
(typically 5-10 MΩ) was compensated by 70-80%. A Digidata 1440A interface (Molecular 
Devices, Sunnyvale, CA, USA) was used to record data at a bandwidth of 2 to 10kHz 





During action potential waveforms (Sections 3.2.2 and 4.2.1) IhERG recordings were corrected 
online for P/N leak subtraction using an interspersed P/4 protocol (McPate et al., 2009a, El 
Harchi et al., 2010). Clampfit 10.2 (Axon Instruments), Origin 2017 (OriginLab Corporation, 
Northampton, MA, USA), Excel 2016 (Microsoft, Redmond, WA), and Prism 7 (Graphpad 
Inc, La Jolla, CA, USA) were all used for data analysis. Using these, a range of equations 
fully quantified the biophysical properties of I560T IhERG: 
Equation 1 
Normalizing hERG tail current values (I) to the maximal tail current value observed during 
the protocol (Imax) and plotting these values against the appropriate voltage command (Vm) 
allowed the half-maximal activation voltage (V0.5) and slope factor for IhERG activation (k) to 
be calculated by fitting with a Boltzmann equation in the form of: 
I=Imax/(1+exp((V0.5−Vm)/k))        (See Figure 6 and Figure 20) 
Equation 2 
The rate of IhERG activation and the recovery from inactivation were calculated by fitting the 
appropriate data with an exponential equation using current (I) normalised against the 
maximal current recorded during the protocol (Imax); the rate constant (K); and the duration of 
the depolarising step (for rate of activation) or repolarising step (for rate of recovery from 
inactivation) preceding IhERG ‘tail’ current measurement (x): 
I = Imax(1-exp(-K x))        (See Figure 7 and Figure 11) 
Equation 3 
IhERG deactivation rates, described as a measure of the fast and slow components of the 
deactivation time-course (𝜏f and 𝜏s respectively), were quantified as a function of the total 
current (I); the current amplitude at time ‘x’; the measure of current represented by 𝜏f and 𝜏s 
(Af and As respectively); and any residual current (C): 






A Goldman-Hodgkin-Katz equation, modified to account for an absence of Na+ in the 
intracellular solution, was used to calculate relative Na+:K+ permeability. The reverse 
potential (E); universal gas constant (R); temperature in Kelvin (T), and Faraday’s constant 
(F) alongside the intra and extracellular concentration of ions ([X]i and [X]o respectively) were 
used to calculate relative ion permeability (pX). 
E = (RT/zF)ln(([K+]o + (pNa/pK) × [Na+]o)/[K+]i) 
Equation 5  
Normalizing hERG tail current values (I) to the maximal value tail current observed during 
the protocol (Imax) and plotting these values against the appropriate voltage command (Vm) 
used to alter IhERG availability allowed the half-maximal inactivation voltage (V0.5) and slope 
factor for IhERG inactivation (k) to be calculated by fitting with a Boltzmann equation in the 
form of: 
I/Imax = 1-(1/(1+exp[(V0.5−Vm)/k]))        (See Figure 9) 
Equation 6 
Fractional inhibition of IhERG by quinidine and sotalol was calculated using maximal hERG 
‘tail’ currents, absolute maximal currents, or current integrals (as appropriate) before 
(IhERG[Control]) and after (IhERG[Drug]) application of drugs : 
Fractional inhibition = 1−(IhERG[Drug]/IhERG[Control]) (See Figure 15, Figure 16 & Figure 24) 
Equation 7 
A standard Hill equation was used to establish concentration-response relations, where IC50 
is the concentration of drug producing half-maximal IhERG inhibition and h is the Hill coefficient 
of the fitting. 







All data are presented as mean ± standard error of the mean (SEM) and p values of less 
than 0.05 were considered significant. These were calculated, as appropriate, using a 
Student’s t-test, Mann-Whitney test or one-way analysis of variance (ANOVA) with 
Bonferroni post hoc test. Statistical significance is denoted throughout by *, **, ** and **** 
represents p values of <0.05, <0.01, <0.001 and <0.0001 respectively. 
2.6 Computational modelling 
Modelling work was all kindly provided by Dr Christopher Dempsey. This used the recently 
published cryo-EM structure of hERG (Wang and MacKinnon, 2017); and a homology model 
of hERG based on a previously published rat EAG (rEAG) cryo-EM structure (Whicher and 
MacKinnon, 2016) which was built using Modeller 9.17 and quality assessed using Procheck 
software. Figures were made using PyMOL (version 1.4; Schroedinger, LLC, New York, NY). 
 
2.7 Performance of in vitro work 
Both the I560T and S631A plasmids were generated in the laboratory prior to my arrival. 
Transfection and cell culture were initially performed by Dr Zhang (University of Bristol), but 
these duties were passed on to myself following suitable training. I collected the majority of 
the electrophysiological data myself, with some also collected by Dr Zhang, in large part to 
ensure correct functioning of all systems whilst my practical and theoretical understanding 







Chapter 3     Effects of the I560T mutation on hERG function 
3.1 Introduction 
The I560T mutation is the first SQT1 causing mutation identified to occur within the S5 
domain of hERG (Hancox et al., 2018). Prior to discovery of the I560T mutation, SQT1 
mutations had been identified in both the N- and C-termini (E50D and R1135H respectively) 
and within the S5-pore linker (N588K) and pore region of the hERG protein (T618I) (Hancox 
et al., 2018), whilst additional inactivation attenuating mutations had been engineered in the 
pore (S620T, S631A) for studies of hERG structure function (Schonherr and Heinemann, 
1996, Ficker et al., 1998, Hancox et al., 1998b, Herzberg et al., 1998, Zou et al., 1998). As 
may be expected, the mutations located within the pore-linker and pore-forming regions 
have been shown experimentally to have a more profound effect on channel function than 
those located at the more distal portions of the channel (Zou et al., 1998, McPate et al., 
2005, Itoh et al., 2009, Hu et al., 2017), and so it is of interest to unravel the extent with 
which the I560T mutation affects the biophysical properties of hERG.  
Whilst many loss-of-function hERG mutations have been found to cause LQTS through a 
reduction in protein trafficking (Thomas et al., 2003, Modell and Lehmann, 2006), no SQT1 
mutations have yet been found to exert effects through increased membrane expression or 
hyperglycosylation of the protein (Hancox et al., 2018). In order to rule out this possibility, 
Harrell et al. (2015) performed western blotting to measure expression of I560T- and WT-
hERG, demonstrating no significant change in either caused by the mutation. This suggests 
the documented QT interval abbreviation with this mutation is a direct result of changes to 
channel gating (Harrell et al., 2015). 
S5 residues have been suggested to be energetically coupled to both S4 residues involved 
in the voltage sensing of activation and inactivation (Perry et al., 2013b), and pore-forming 
residues which are critical for channel inactivation (Perry et al., 2013a). Furthermore, a 





the selectivity filter, caused a positive shift in half-maximal activation and slowed channel 
deactivation (Lees-Miller et al., 2009). Whilst confirmation of interactions between residues 
are outside the intended scope of this study, by fully characterising the biophysical 
properties of I560T-hERG, the work presented here could offer a basis for more targeted 
further work. In addition to this, by determining the effects of the mutation on binding of 
quinidine and sotalol, the study will offer insight into the structural effects of the mutation as 
well as potential therapeutic strategies for the patient. The interplay between S5 and the 
range of key hERG domains described in the literature suggests that the effects of the I560T 
mutation may extend beyond the only the voltage-dependence of inactivation as described 
by Harrell et al. (2015), and so additional hERG properties must be defined in order to 
characterise further the way in which the mutation facilitates shortening of the QT interval.  
 
3.2 Results 
3.2.1 Biophysical properties of I560T-hERG 
3.2.1.1 Effects of the I560T mutation on hERG activation 
The upper panels of Figure 6A show representative current traces elicited by application of 
the voltage protocol shown in the lower panels. Consistent with earlier studies (McPate et 
al., 2005, Zhang et al., 2011) a two second depolarising command was applied from a 
holding potential of -80mV to potentials between -40mV and 60mV. Subsequently, a 
repolarisation command to -40mV was applied to relieve channel inactivation, resulting in the 
archetypal resurgent IhERG ‘tails’. Figure 6Ai shows the well-established characteristics of WT 
IhERG, with the current upon depolarisation rising rapidly and then plateauing; and the 
repolarisation command causing a rapid increase in hERG current (IhERG) as inactivation was 
removed, followed by slower deactivation (Sanguinetti and Jurkiewicz, 1990, Sanguinetti et 
al., 1995, Spector et al., 1996, Zhou et al., 1998). By contrast, following the same protocol, 





repolarisation, the mutant channel’s tail current was typically smaller than that seen at the 
end of depolarisation across the positive voltage range.  
The relationship between voltage and IhERG (I-V relations) was determined by plotting the 
magnitude of the current following the depolarising pulse (“end pulse” current) against the 
applied voltage, with the magnitude of end pulse current reflecting both channel activation 
and inactivation. This is shown in Figure 5B, where WT IhERG increased progressively up to 
0-10mV and then declined at the more positive potentials as inactivation increased. IhERG 
magnitude was plotted as current density (pA/pF) in order to normalize data for cell size 
(capacitance reflecting cell membrane surface area). Although I560T-hERG exhibited a 
Figure 6: I-V relationship for WT and I560T-hERG. (A) Representative current traces for WT (i) and 
I560T (ii) hERG channels elicited by the protocol shown below, with only selected traces shown for 
clarity. (B) Mean I-V relations for end pulse WT and I560T IhERG. Current was normalised to 
capacitance reflecting cell membrane surface area. (C) Mean normalized tail current I-V relations. 
Currents were normalized to the peak current recorded during the protocol for each cell and fitted 









































































































































































higher current density compared to the WT (e.g. following a 20mV command pulse; 298.8 ± 
60.9pA/pF for I560T vs. 132.1 ± 26.5pA/pF for WT; n=17 vs. n=8; p<0.001), it followed a 
similar current progression at negative potentials with current density peaking at 10mV. 
Through the initial positive voltages however, I560T IhERG remained comparatively higher, 
with little drop in current seen until commands to +40/+50 mV pulse were applied, whereas 
almost half the WT IhERG had reduced prior to this. Rectification at 60mV increased however; 
thus, the end pulse I-V relation for I560T-hERG showed a region of negative slope, just 
shifted somewhat compared to the WT channel.  
As peak tail currents represent the level of channel activation in the absence of inactivation, 
plotting these normalized values across the voltage range allows the voltage dependence of 
activation to be established (Figure 6C) (Sanguinetti and Jurkiewicz, 1990, Trudeau et al., 
1995, Zhou et al., 1998, McPate et al., 2005). There was no change in the half maximal 
activation voltage (V0.5) between the WT and mutated channels (-21.07 ± 1.29mV vs. -21.43 
± 1.41mV respectively; n= 8 vs. n=17; p>0.05), but a change in the slope of the activation 
relation (k) was identified (6.61 ± 0.15mV vs. 12.55 ± 2.14mV; n= 8 vs. n=17; p<0.01).  
To establish the effects of the I560T mutation on the time-course of IhERG activation, an 
‘envelope of tails’ protocol was used (Figure 7) as employed in other studies (e.g. Zhang et 
al., 2011, El Harchi et al., 2012., Helliwell et al., 2018). From a holding potential of -80mV, a 
depolarising step to 20mV of variable duration was applied, followed by a 4 second 
repolarising step to -40mV. As the repolarising step removes IhERG inactivation, varying the 
duration of the depolarising step (from 10ms to 810ms) allows IhERG tail currents to be used 
to establish the rate at which the channel is activated. Representative currents for WT and 
I560T IhERG following this protocol are shown in Figures 6Ai and 6Aii respectively. Plotting 
normalized peak tail currents and fitting them with Equation 2 (Figure 7B) shows a significant 
decrease in the mean time-constant of activation caused by the I560T mutation (65.4 ± 





3.2.1.2 Effects of the I560T mutation on the fully activated I-V relations 
In order to quantify IhERG deactivation and compare the fully activated I-V relation between 
WT and mutant channels, the protocol seen in the lower panel of Figure 8A was used, as 
seen previously (Spector et al., 1996, Hancox et al., 1998a, Zhou et al., 1998, McPate et al., 
2005, Zhang et al., 2011). From a holding potential of -80mV, membrane potential was 
stepped to +40mV for 500ms to allow the channels to activate and inactivate fully. Following 
this, repolarising voltage commands were applied for 5 seconds at 10mV steps between -
100mV and 40mV in order to relieve inactivation to different extents, producing resurgent 
current tails of different magnitudes, which then deactivated. This allowed the rate of 
 
Figure 7: Time dependence of WT and I560T-hERG activation. (A) Representative traces for WT (i) 
and I560T (ii) IhERG elicited by the ‘envelope of tails’ protocol shown in the lower panels. (B) Peak tail 
currents at each timepoint were normalised to the maximal current recorded during the protocol for 































































































deactivation to be quantified across a wide voltage range. As can be seen in the 
representative traces of Figure 8Ai, WT tail currents rose as expected as the membrane 
potential became less negative, peaking at -20mV (McPate et al., 2005, Zhang et al., 2011). 
Similarly, tail current plateaus also increased as channel activation increased throughout the 
negative potentials, however at positive repolarising voltages range peak tail currents as 
substantial channel inactivation remained (see 20mV trace). I560T IhERG followed a similar 
pattern under the same conditions (Figure 8Aii), albeit with a slightly more positive peak at -
10mV. 
Separate fast (𝝉f) and slow (𝝉s) components to hERG deactivation have previously been 
established and consequently a bi-exponential fitting (Equation 3) of the traces in Figure 8A 
can be used to quantify deactivation rates across the voltage range (Sanguinetti et al., 1995, 
Zhou et al., 1998, Wang et al., 2000, McPate et al., 2005, Zhang et al., 2011). At voltages 
above -20mV, the level of deactivation became too small to fit accurately. As can be seen in 
Figure 8B and 8C, 𝝉f and 𝝉s were modestly increased in I560T compared to WT at some 
voltages, although this was slightly more prominent for the fast component. As shown in 
Figure 8D however, the more significant increase in 𝝉f compared with 𝝉s was not sufficient to 
augment the proportion of deactivation mediated by either component to a significant level. 
Together, these data indicate a slight decrease in the rate of deactivation from a fully 
activated state.  
By normalising both inward and outward tail currents to the maximal current recorded during 
the protocol for each cell, I-V relations from the fully activated state have also been establish 
as seen previously (Figure 8E) (Sanguinetti et al., 1995, Zhou et al., 1998, McPate et al., 
2005, Zhang et al., 2011). This demonstrated a modest but statistically significant positive 
shift in the reversal potential (Erev) of IhERG caused by the mutation (-85.05 ± 0.53mV to -
80.34 ± 1.4mV; n=5 vs. n=11; p<0.05; Figure 8E). Using a modified Goldman-Hodgkin-Katz 





to reflect a modest decrease the channel’s selectivity towards K+ as the Na+:K+ permeability 
ratio changed from 0.010 to 0.016. 
 
Figure 8: Fully activated I-V relations for WT and I560T-hERG. (A) Representative current traces 
elicited by the protocol shown in the lower panel of figures for WT (i) and I560T (ii) hERG, with only 
selected sweeps shown for clarity. (B, C) Fast (𝝉f) and slow (𝝉s) time constants of deactivation 
respectively, calculated by fitting current traces with Equation 3. (D)  Fraction of deactivating current 
mediated by the fast component at voltages of -100mV to -20mV. (E) Peak tail currents at each 
voltage were normalized to the peak current recorded during the protocol for each cell to give the 











































































































































































































































































































































































































































































































































































































































3.2.1.3 Effects of the I560T mutation on hERG inactivation 
Figure 9A and the lower panels of 8B show the voltage protocol used to study further 
inactivation properties of WT and I560T-hERG (Zou et al., 1998, McPate et al., 2005, Sun et 
al., 2011, El Harchi et al., 2012). From a holding potential of -80mV, cell membrane potential 
was stepped to 40mV and held at this potential for 500ms, allowing the channel to activate 
and inactivate fully. Subsequently, a brief 2ms pulse to different repolarization potentials (-
140mV to 50mV) was applied to remove inactivation to varying degrees, before a third pulse 
returned the membrane potential to 40mV. As can be seen in Figure 9B, reapplication of 
depolarising commands to 40mV resulted in rapid IhERG reflective of channel availability at 
each given voltage. By analysing the current following this third pulse (Figure 9Bi and 8Bii), 
the voltage dependence and time course of the inactivation gating was calculated. In order 
to correct for any deactivation, recorded traces were fitted with a single exponential fitting 
(Equation 5) and extrapolated back to the start of the third step, as described previously 
(Smith et al., 1996, Zou et al., 1998, McPate et al., 2005, Zhang et al., 2011). 
For each cell, calculated peak currents were normalised to maximal current obtained during 
the protocol and plotted against voltage to establish voltage dependence (Figure 9C). The 
I560T mutation was shown to shift the V0.5 of IhERG inactivation positively by ~24mV (-41.79 ± 
3.47mV for I560T vs. -66.25 ± 1.91mV for WT; n=6 vs. n=13; p<0.001), with an 
accompanying decrease in k value (-20.15 ± 0.62 for I560T vs. -25.31 ± 1.22 for WT; n=6 vs. 
n=13; p<0.05). As is apparent in the representative traces shown in Figure 9B, the mutated 
channel also increased the time-course of the development of inactivation, with a time 
constant more than double that seen in WT (2.31 ± 0.17 for WT vs. 4.72 ± 0.36 for I560T; 
n=6 vs. n=13; p<0.001; Figure 9D). This change in inactivation was also seen to affect 
steady state IhERG greatly. Using the product of Equations 1 and 5, with V0.5 and k values 
derived from the fitted activation and inactivation plots (Figure 10A), this ‘window’ current 
was calculated across a wide voltage range (Figure 10B) to show a significant increase in 






Figure 9: Voltage and time dependence of inactivation for WT and I560T-hERG. (A) Voltage 
protocols used to establish IhERG inactivation. The highlighted sections are those magnified in lower 
panels of B. (B) Representative traces for WT (i) and I560T (ii) IhERG. A pulse at every 10mV from -
140mV to 50 mV was used to elicit current, with only selected traces shown here for clarity. (C) The 
voltage dependence of inactivation. Maximal IhERG following the third pulse were normalized to the 
peak current recorded during the protocol for each cell and fitted with Equation 5. (D) Summary of 
the time-constant for the development of inactivation for WT and I560T IhERG following repolarisation 
commands to 120mV.  































































































































































































Additionally, the rate at which channels recover from inactivation has been investigated 
using the protocol shown in Figure 11A and expanded upon in the lower panels of Figure 
11B. From a holding potential of -80mV, a depolarising step to 40mV was applied to allow 
the channels to reach a steady state of activation and inactivation. A brief, -40mV, 
repolarising pulse of 2ms to 20ms was then applied before a second depolarising pulse to 
40mV. Plotting the normalized peak tail current (Figure 11C) allows investigation of the time- 
span necessary for complete transition to the open, activated state. As can be seen in Figure 
11C, there was no significant difference between the time-constants for the recovery from 




Figure 10: WT and I560T-hERG window current. (A) Superimposed activation and inactivation 
curves for WT (i) and I560T (ii) IhERG respectively as initially plotted in Figure 6C and Figure 9C. (B) 
Product of activation and inactivation parameters plotted against voltage to show steady state WT 
and I560T IhERG. 






























































































































Figure 11: Time dependence of WT and I560T-IhERG recovery from inactivation. (A) Voltage protocol 
used to establish rate of recovery, with the highlighted section being expanded upon in the lower 
panels of (B). (B) Representative traces for WT (i) and I560T (ii) IhERG. (C) Peak tail currents at each 
timepoint were normalised to the maximal current recorded during the protocol for each cell and fitted 
with Equation 2 to quantify the rate of recovery from inactivation. 

































































































































3.2.2 Physiological consequences of the I560T mutation  
3.2.2.1 Effects of the I560T mutation on IhERG profile during ventricular AP 
The conventional voltage clamp techniques used above constitute an excellent means to 
understand basic channel kinetic properties through specific square voltage command 
protocols. Despite this, the use of physiological action potentials as stimuli during voltage 
clamp (AP clamp) in addition to the more traditional step protocols is valuable as it allows 
recordings to account for the more dynamic history of membrane potential experienced 
during physiological events (Hancox et al., 1998a, Noble et al., 1998). Figure 12A shows the 
mean IhERG produced in response to a ventricular AP, with the AP itself shown 
simultaneously (McPate et al., 2009a, El Harchi et al., 2010). Following the initial peak of the 
AP at ~60ms in Figure 12Ai, hallmark IhERG characteristics were exhibited in the WT with 
current limited during the early stages of the AP and, as the membrane potential decreased, 
inactivation was progressively removed and so IhERG increased, peaking in phase 3 of the 
AP. From the start of phase 2 however, I560T IhERG continued to increase in a relatively 
linear fashion, with peak current still occurring in phase 3 of the action potential (Figure 
12Aii).  
Figure 12B, which shows instantaneous I-V relationship established throughout the 
ventricular AP, with repolarisation occurring from the right to the left of the plots, highlights 
that although both WT and I560T IhERG peaked late during the ventricular AP, the mutation 
caused a significant positive shift in the voltage at which this occurs (Figure 12B; I560T -11.9 
± 3.4mV vs. WT -29.7 ± 2.7mV; n=19 vs. n=5; p<0.05, and so I560T IhERG peaked earlier 
during repolarisation. In addition to this earlier timing, the total charge passed by the channel 
(current integral) was 2.6-fold larger than that of WT IhERG (Figure 14B; p<0.01). Figure 12C 
shows the instantaneous changes in conductance throughout repolarisation. As can be seen 
in Figure 12Ci, WT G-V relations increased progressively throughout the early stages of the 






Figure 12: WT and I560T-IhERG response to a ventricular AP. (A) Mean WT (i) and I560T (ii) IhERG 
profile (shown in black) during a ventricular AP (shown in grey). Current was normalised to 
capacitance reflecting cell membrane surface area. (B) Mean I-V relations recorded during 
repolarisation in a ventricular action potential. Current was normalised to the maximal current 
recorded during the protocol for each cell, with these values used to establish mean current at each 
given voltage. (C) Mean G-V relations recorded during repolarisation in a ventricular AP. For (B, C) 
the arrows represent the direction of repolarisation. For all figures, n=5 for WT and n=19 for I560T. 


























































































































































































ionic driving force increased much earlier in the AP (between 20mv and -30mV) and also 
remained high over a larger voltage range (Figure 12Cii). 
 
3.2.2.2 Effects of the I560T mutation on IhERG profile IhERG during atrial and Purkinje fibre AP 
To establish whether the different voltage, duration and plateau phases of action potentials 
in other cardiac tissue types would affect I560T IhERG to a similar extent as the ventricular 
AP, both atrial and Purkinje fibre (PF) stimuli were also applied to the cells (Figure 13), as 
used previously (El Harchi et al., 2009, El Harchi et al., 2010, Milnes et al., 2010). As can be 
seen, the plateau phase of the atrial AP (Figure 13Ai) is both shorter in duration and occurs 
at a voltage more negative than the ventricular AP, and as a result the elicited IhERG was 
much smaller. Although this lower plateau reduced hERG activation, inactivation was also 
diminished and therefore a more dome-shaped IhERG profile was produced. I560T IhERG again 
produced a larger current integral (Figure 14B; 2.3-fold; p<0.001) than WT, but the reduced 
involvement of inactivation meant the current profile was similar under both the WT and the 
mutant condition. This was supported by peak IhERG occurring at same stage of the AP in WT 
cells as cells expressing I560T-hERG (Figure 13Aii, -24.0 ± 2.5mV vs. -24.4 ± 2.3mV; n=15 
vs. n=16; p>0.05). 
The PF AP (Figure 13B) is an intermediary between the atrial and ventricular APs, with its 
plateau phase being at an intermediate with regards to both duration and voltage. This was 
reflected in the profile of WT IhERG which underwent some inactivation during the early stages 
of repolarisation and peaked during phase 3 at voltage comparable to that of the ventricular 
AP (Figure 13Bii; -35.1 ± 0.8mV; n=7) before the channel deactivated. Similar to other APs, 
I560T IhERG carried a 2.2-fold greater charge throughout the waveform compared to WT IhERG 
(Figure 14Bi; p<0.05). As can be seen in Figure 13Bii, the mutant channels also caused 
peak IhERG to occur significantly earlier during repolarisation (-17.5 ± 3.5mV; n=7; p<0.001). 
In summary, these data show that the I560T mutation increased IhERG in response to APs 





APs, and therefore the ratio of total IhERG was little different between AP types (Figure 14A, 
B). In addition to this, peak IhERG occurred earlier during repolarisation only in response to 





Figure 13: WT and I560T-IhERG response to atrial and Purkinje fibre APs. (Ai) Mean profile of WT and 
I560T IhERG during atrial AP. (Aii) Mean I-V relations recorded during repolarisation in an atrial AP. 
(Bi) Mean profile of WT and I560T IhERG during Purkinje fibre AP. (Bii) Mean I-V relations during 
Purkinje fibre AP. For all figures, WT IhERG is shown in grey whilst I560T IhERG is in black. For (Ai and 
Bi), current was normalised to capacitance reflecting cell membrane surface area. For (Aii and Bii) 
the arrows represent the direction of repolarisation and current was normalised to the maximal current 
recorded during the protocol for each cell, with these values used to establish mean current at each 
given voltage. 























































































































































































Figure 14: Comparison of WT and I560T-IhERG density and timing during ventricular, atrial and PF 
APs. (A) Comparison of total charge passed during different AP conditions in WT (i) and I560T (ii) 
hERG-expressing cells. (B) Comparison of total WT and I560T IhERG during each AP. For both of (A, 
B), total charge was calculated by integrating current traces normalized to cell capacitance. (C) Mean 
voltage at which peak IhERG occurred during each AP for WT and I560T channels. In all figures, as 





























































































































3.2.3 Response of I560T-hERG to quinidine and sotalol 
3.2.3.1 Response of WT and I560T-hERG to quinidine 
The response of IhERG to quinidine and sotalol was measured using a standard step protocol 
used in previous studies from this laboratory (e.g. McPate et al., 2008, Zhang et al., 2011, El 
Harchi et al., 2012). This was comprised of a 2 second depolarising command to 20mV 
followed by a 4 second repolarising command to -40mV, followed by a return to the -80mV 
holding potential (lower panels of Figure 15A). A 12 second start-to-start interval was used, 
with superfusion of drug occurring until IhERG reached a steady state.  
 
Figure 15:  Inhibition of WT and I560T-IhERG by quinidine. (A) Representative traces of WT (i) and 
I560T (ii) IhERG in the absence (black) and presence (grey) of 1μM quinidine. (B) Concentration-
response relations for inhibition of WT and mutant IhERG, with fractional block calculated using 































































































The class Ia antiarrhythmic quinidine has been shown to prolong the QT interval in SQTS 
patients (Gaita et al., 2004, Wolpert et al., 2005) and inhibit Ikr in vitro (Paul et al., 2002, 
Wolpert et al., 2005), whilst its binding is only modestly altered by the attenuation of 
inactivation (Lees-Miller et al., 2000a, McPate et al., 2006, McPate et al., 2008). 
Consequently, its effectiveness in inhibiting I560T IhERG has been evaluated in this work. The 
upper panels of Figure 15A show representative traces of WT and I560T IhERG in the absence 
(black) and presence (grey) of 1μM quinidine, with the application of quinidine clearly 
reducing IhERG throughout the protocol for both WT and mutant cells. Plotting IhERG tail 
currents in response to 0.1-10μM quinidine (Figure 15B; Equation 7) established a half-
maximal inhibitory concentration (IC50) 2.3-fold larger for I560T IhERG than that of the WT 
(0.88 ± 0.14μM for I560T vs. 0.38 ± 0.03μM for WT; p<0.01), with derived h values of 0.86 ± 
0.06 (WT) and 0.7 ± 0.09 (I560T; p>0.05). 
 
3.2.3.2 Response of WT and I560T-hERG to sotalol 
In contrast to quinidine, binding of the class III antiarrhythmic sotalol to hERG has been 
shown as heavily dependent upon inactivation gating (Numaguchi et al., 2000, Brugada et 
al., 2004, Wolpert et al., 2005), and so its evaluation in parallel to quinidine may aid 
understanding of the mutation’s effects on relatively well understood drug binding 
mechanisms as well as providing insight into the potential therapeutic benefits of the drug. 
The upper panels of Figure 16A shows representative traces of WT and I560T IhERG in the 
absence (black) and presence (grey) of 100μM sotalol. Plotting IhERG tail currents in response 
to 1-1000μM sotalol (Figure 16) shows no significant difference in IC50 between the WT and 
mutant channels (135.6 ± 47.4 for WT vs. 88.74 ± 35.3 for I560T; p>0.05; Equation 7), and 







 WT IC50 (μM) I560T IC50 (μM) WT h  I560T h 
Quinidine 0.38 ± 0.03 0.88 ± 0.14 (p<0.01) 0.86 ± 0.06 0.7 ± 0.09 
Sotalol 135.6 ± 47.4 88.74 ± 35.3 (p>0.05) 0.49 ± 0.08 0.35 ± 0.06 




Figure 16: Inhibition of WT and I560T-IhERG by sotalol. (A) Representative traces of WT (i) and I560T 
(ii) IhERG in the absence (black) and presence (grey) of 100μM sotalol. (B) Concentration-response 
relations for inhibition of WT and mutant IhERG, with fractional block calculated using Equation 6. A 





























































































3.3 Summary I560T data 
Property WT I560T Significance 
IhERG properties during voltage clamp 
Current density at 20mV 
(pA/pF) 
132.1 ± 26.5 (n=8) 298.8 ± 60.9 (n=17) p<0.001 
V0.5 (activation) (mV) -21.07 ± 1.29 (n=8) -21.43 ± 1.41 (n=17) p>0.05 
k (activation, mV) 6.61 ± 0.15 (n=8) 12.55 ± 2.14 (n=17) p<0.01 
Activation time constant 
(ms) 
65.4 ± 3.5 (n=5) 19.6 ± 1.7 (n=7) p<0.0001 
Erev (mV) -85.05 ± 0.53 (n=5) -80.34 ± 1.4 (n=11) p<0.05 
Time constant for recovery 
from inactivation (ms) 
1.84 ± 0.08 (n=10) 2.05 ± 0.17 (n=18) p>0.05 
V0.5 (inactivation) (mV) -66.25 ± 1.91 (n=6) -41.79 ± 3.47 (n=13) p<0.001 
k (inactivation, mV) -20.15 ± 0.62 (n=6) -25.31 ± 1.22 (n=13) p<0.05 
Time constant (ms) 2.31 ± 0.17 (n=6) 4.72 ± 0.36 (n=13) p<0.001 
Voltage of maximal IhERG during AP clamp 
Ventricular AP (mV) -29.7 ± 2.7 (n=5) -11.9 ± 3.4 (n=19) p<0.05 
Atrial AP (mV) -24.0 ± 2.5 (n=15) -24.4 ± 2.3 (n=16) p>0.05 
Purkinje fibre AP (mV) -35.1 ± 0.8 (n=7) -17.5 ± 3.5 (n=7) p<0.001 
Current integral during AP clamp 
Ventricular AP (pC/pF) 23.8 ± 2.6 (n=5) 60.8 ± 8.2 (n=19) p<0.01 
Atrial AP (pC/pF) 3.7 ± 0.6 (n=15) 8.4 ± 1.4 (n=16) p<0.001 
Purkinje fibre AP (pC/pF) 15.1 ± 3.2 (n=7) 29.7 ± 6.6 (n=7) p<0.05 








3.4.1 Effects of the I560T mutation on hERG properties 
Although a partial electrophysiological characterisation of I560T IhERG has been previously 
published (Harrell et al., 2015), this study provides a more complete evaluation of the 
mutation’s effects, describing for the first time for I560T-hERG: the time-dependence of 
activation; the fully activated I-V relation; ion selectivity; deactivation rates; the rate of 
recovery from inactivation; the time course of inactivation; and the current timing and voltage 
dependence (I-V relations) during cardiac action potentials. In addition, the pharmacological 
information on quinidine and sotalol is novel. 
Where direct comparison is possible, the results presented here are generally in agreement 
with those published previously, with a comparative increase in current density (I560T IhERG 
2.3-fold larger than that of WT in my work, 2.5-fold previously; Figure 6B) and no change in 
the half maximal voltage of activation seen in either study (Figure 6C; Harrell et al., 2015). 
My work, however, has shown a greater positive shift in inactivation V0.5 (~24mV vs. ~14mV; 
Figure 9C). Both investigations were performed at 37°C using similar recording solutions 
and techniques, with the only major difference in methods being in the use of a COS-7 cell 
line in the original work by Harrell et al. (2015). It is possible that this difference is related to 
unknown, natively expressed co-assembling proteins; proteins involved with post-
translational modification of hERG; or proteins associated with biogenesis and assembly 
which exist to varying extents in different cell lines (Vandenberg et al., 2012, Li et al., 2017), 
but exact determination of the variation is outside the scope of this work. Despite the larger 
shift in inactivation demonstrated by my work, the recorded V0.5, (inactivation) published by Harrell 
et al. (2015) is significantly (~29mV) more positive than my own findings. Similarly, their V0.5, 
(inactivation) for WT-hERG, was also dramatically shifted compared to established literature from 
this and other laboratories (Zou et al., 1998, McPate et al., 2005, Vandenberg et al., 2006, 
Zhang et al., 2011, Harrell et al., 2015), and consequently it is possible that the shift in 





these differences, the positively shifted V0.5 (inactivation), alongside the change seen in slope (k) 
value, results in considerably less IhERG inactivation occurring across the majority of 
physiological voltages (Figure 9C), including those at which AP plateaus occur. As has been 
described in studies of other mutations which attenuate inactivation, the resulting increase in 
IhERG will drive repolarisation and QT interval shortening (McPate et al., 2005, McPate et al., 
2009a). 
In addition to changes in the voltage dependence of inactivation, conventional voltage clamp 
demonstrated more widespread effects of the I560T mutation on gating properties of hERG, 
with changes in the rate of activation, deactivation and inactivation all seen. The faster time 
course of activation (Figure 7) would lead to increased IhERG activation at a very early stage 
of an AP, however it is also notable that the time course is still significantly slower than that 
of the development of inactivation presented in this study (Figure 9D). The differences in 
voltage during the relevant protocols makes the exact time courses difficult to compare, but 
the decreased speed in the development of inactivation demonstrated by my work (Figure 
9D) combined with this increase in rate of activation are anticipated to contribute to 
increased IhERG. 
A slower rate of deactivation has been shown as the primary mechanism through which 
R1135H-hERG causes SQT1 (Itoh et al., 2009), with this being demonstrated using in silico 
simulations as sufficient to abbreviate the QT interval clinically (Wilders and Verkerk, 2010). 
Similarly, a faster time course of deactivation has been shown to cause LQTS (Chen et al., 
1999).  Although the I560T mutation only causes a modest decrease in the rate of 
deactivation at some voltages (Figure 8B, C), the increase in IhERG that this causes may 
contribute to some extent to the abbreviation of the QT interval. Despite this QT shortening, 
these slowed rates of deactivation may be in fact confer protection against arrhythmia, as 
the residual IhERG could be protective against subsequent premature stimulation (See Figure 
4C). Thus, the I560T mutation may confer some protection against re-entrant circuits (Lu et 





With hERG’s inactivation being dependent upon collapse of the selectivity filter (Liu et al., 
1996, Hoshi and Armstrong, 2013), it is perhaps no surprise that mutations affecting 
inactivation also commonly cause changes in Erev and ion permeability (Jiang et al., 2005, 
Vandenberg et al., 2012). This is in agreement with previous data showing the hERG S5 
mutation, L532P, to cause a similar shift in inactivation V0.5 (+32mV) accompanied by an 
identical ~1.6-fold increase in Na+:K+ permeability ratio (Zhang et al., 2011) and the larger 
shift in inactivation caused by N588K (+90mV) to link to a ~2.7-fold increase in Na+:K+ 
permeability ratio (McPate et al., 2005). Despite these associations, the separate processes 
of inactivation gating and ion selectivity mean that this effect has not been described for all 
mutations (Fan et al., 1999, Sun et al., 2011), but mutations to a range of further residues 
involved in inactivation gating in the S5-P linker have also been shown to influence K+ 
selectivity (Jiang et al., 2005, Tseng, 2006), and the differences in impact on ion selectivity 
are at least partially a consequence of the direction in which the residues face within the α-
helices (Liu et al., 2002). Similarly, mutations within the selectivity filter itself have been 
shown to affect selectivity to different extents (Lees-Miller et al., 2000b, Sun et al., 2011). In 
work that linked residues more distal to the selectivity filter to ion selectivity, K+ selectivity 
was shown to be dependent upon interactions between the selectivity filter and S5 through 
energetic linkage of given residues (Perry et al., 2015), and so my work is in agreement with 
previous work suggesting that both S5 residues, and those which attenuate inactivation can 
also affect ion selectivity. 
The increased current seen across a wide range of physiologically relevant voltages (Figure 
6B) and during ventricular, atrial and Purkinje fibre AP commands (Figure 12A & Figure 
13Ai, Bi) constitute compelling evidence of how I560T IhERG can accelerate repolarization 
and drive a reduction in QTc interval. This larger current passed during repolarisation by the 
channels in both upper and lower cardiac chambers as well as throughout the Purkinje fibres 
would shorten phases two and three of the AP, lowering the membrane potential more 





further reinforced by the earlier timing of peak IhERG during ventricular and PF APs (Figure 
12B, Figure 13Aii, Bii). As QTc interval has a direct relationship with the effective refractory 
period (ERP), which is vital in the protection of cardiac tissues against fibrillation (Gaita et 
al., 2003), it is reasonable to conclude that that mutation-driven shortening of the QTc 
interval could predispose to arrhythmogenesis by abbreviating refractoriness (expanded 
upon below in Section 3.4.3). To summarise: the data obtained show that the I560T mutation 
affects a range of hERG properties, each of which contribute to increased IhERG and 
augmentation of IhERG timing to varying extents during cardiac action potentials. In turn, these 
alterations likely contribute to the abbreviation of the QT interval, predisposing the patient to 
arrhythmia.  
 
3.4.2 Structural context of the I560T mutation 
The underlying structural mechanism(s) by which the I560T mutation causes these changes 
in IhERG kinetics are currently unclear and this has not been helped by the lack of a detailed  
hERG structure, with previous structural inferences depending on the use of homology 
modelling (Lees-Miller et al., 2009, Perry et al., 2010, Zhang et al., 2011, Cavalli et al., 2012, 
Durdagi et al., 2012, Perry et al., 2013b, Melgari et al., 2015, Saxena et al., 2016, Wang et 
al., 2016, Phan et al., 2017). Recently, however, the first cryo-electron microscopy (cryo-EM) 
structure of hERG was published using an open pore, activated (depolarised) conformation 
(Wang and MacKinnon, 2017). Using this structure (Figure 3B, Figure 17A), it can be seen 
that the I560 side chain faces membrane lipids, with a distance too great to suggest direct 
interaction with other residues in the S5 domain; adjacent S6 domain or the opposing S4 
domain. The notion that I560 does not interact directly with the voltage sensing domain is 
further supported by mapping the residues to a closed pore rEAG structure with a high level 
of homology to hERG (Whicher and MacKinnon, 2016). As can be seen in Figure 17, 
modelling I560 using both the new Cryo-EM structure and the rEAG structure which has 





Perissinotti et al., 2018) shows highly comparable results, with the residue facing membrane 
lipids under both conditions.  
 
A separate study investigated ‘energetic coupling’ between S4 and S5 residues by 
introducing double mutations and establishing whether their effects on inactivation were 
additive or overlapping (Perry et al., 2013b). This work showed a coupling between I560 and 
hydrophobic residues involved in the voltage sensing of inactivation on the S4 domain (L529 
and V535). In the context of another homology model (Kv1.2/2.1 chimera; Long et al, 2007) 
the distance between I560 and S4 residues was stated to be too large for a direct 
interaction, supporting findings from the more recent models. The energetic coupling data 
however, suggests an allosteric effect on S4 possibly via modulation of interactions with the 
lipid membrane, and this represents a potential mechanism for the attenuation of inactivation 
caused by the I560T mutation. One possible explanation, which is consistent with the S4/S5 
energetic coupling data, as well as the data described above which highlighted coupling 
between the selectivity filter and S5 (Perry et al., 2015), is that of threonine induced bending 
of transmembrane α-helices. It is well documented that rather than interact with lipid chains, 
the polar sidechains of both serine and threonine preferentially form hydrogen bonds with 
amino acid residues three or four residues closer to the N-terminal than themselves 
v 
Figure 17: Structural context of the I560 residue. (A) Construct of hERG built using the recent cryo-
EM structure (Wang and MacKinnon, 2017). (B) hERG model built on rEAG cryo-EM structure 
(Whicher and MacKinnon, 2016). In both, residues near I560 (within 7Å) are highlighted in yellow, 
but the distance between these and I560 is still too great for direct interactions. Provided by Dr 





(Ballesteros et al., 2000, del Val, 2012, Xu et al., 2016). Consequently, the isoleucine to 
threonine substitution may facilitate the formation of a hydrogen bond between T560 and 
T556 or F557 in hERG and would increase the bending angle of the helix. This will alter the 
way in which a number of local amino acids could interact with multiple key hERG structures, 
potentially affecting interactions between S5 and the S4 regions responsible for both 
activation and inactivation gating (Perry et al., 2013b) as well as with the pore domain (Lees-
Miller et al., 2009, Perry et al., 2015). This is supported by the cryo-EM structure and the 
tight ‘knobs-into-holes’ packing (steric contacts occurring between complimentary helices; 
Eilers et al. (2002)) it shows between residues on the pore helix (including T618) and the 
nearby A651 and A656 (Figure 18A). Even minor perturbation of these interactions as may 
be caused by the amino acid substitution and the possible induction of helices bending and it 
is likely that this will influence channel gating and ion selectivity considering the critical role 
the pore helix has in channel function (Hancox et al., 1998b, Lees-Miller et al., 2009, Perry et 
al., 2013a). The cryo-EM structure also highlights a region of S1 which interacts with the 
pore helix and S5 (Figure 18B), and it is possible that an alteration to this interaction may 
have further effects for activation, inactivation and deactivation gating (Zhang et al., 2005, 
Colenso et al., 2013, Phan et al., 2017). 
Although the pursuit of a complete structural basis for the mechanisms by which the I560T 
mutation interferes with the biophysical properties of hERG is outside the scope of my work, 
the current literature provides potential mechanisms by which the diverse effects found in my 
study could be caused. Although this is aided by the recently published Cryo-EM structure 
and more widely used homology models, hERG’s range of gated states mean that more 
work needs to be done to capture accurately the arrangement of hERG in order to 







3.4.3 Mechanisms of arrhythmogenesis 
The proband in the initial work by Harrell et al. (2015) suffered from palpitations and near 
syncope triggered by paroxysmal atrial fibrillation (AF) and atrial flutter which was treated 
using catheter ablation (CA). Following this, a QTc interval of 319ms was recorded, but there 
is no report of the measured QTc interval prior to CA or the timespan over which this 
developed and so it is not possible to describe the degree of shortening caused by the CA. 
This is further complicated by case reports in which catheter CA has been successfully used 
to treat SQTS (Pavão et al., 2014) and LQTS has been triggered by CA (Mantziari et al., 
2011). To my best knowledge, this the only patient described in the literature to have SQTS 
defined following CA, and so it is possible that either the onset is an unfortunate and rare 
consequence of the difficulties in understanding and detecting ablation targets (Dharmaprani 
et al., 2018, Jansen et al., 2018) combined with the I560T mutation increasing propensity for 
 
Figure 18: S5 interactions which may be perturbed by the I560T mutation. (A) The residue adjacent 
and one further helical turn from I560 (A561 and A565) tightly pack with complementary pore helices, 
forming interactions with A614, L615, T618 and F619 (B) The I560 residue cannot interact with S4 
of the VSD, but the extracellular half of the S5 helix can interact with both S1 and the pore helix 
through interactions occurring within the dotted circle (side chains not shown). For both figures, 
constructs were built using the recent cryo-EM structure (Wang and MacKinnon, 2017) and provided 





arrhythmia; or that the presenting AF caused by the I560T mutation resulted in difficulties in 
accurately measuring the QT interval prior to ablation. Regardless, this increase in 
susceptibility to arrhythmia is reinforced by the sudden death of the proband’s brother and 
father (Harrell et al., 2015). Interestingly, studies have however shown AF patients with a 
shorter QTc interval to have reduced recurrent episodes of AF following CA compared to 
those with a longer QTc interval, although it must be noted that the lowest QTc interval in 
these were still higher than that of the I560T-hERG patient (Liu et al., 2015, Ma et al., 2016).  
As described, the increased current density carried by I560T-IhERG will accelerate 
repolarisation and shorten the APD and the ERP (McPate et al., 2005, Rudic et al., 2014, 
Hancox et al., 2018). In turn, this causes a decrease in excitation wavelength which supports 
the formation of re-entry circuits and re-entrant arrhythmias. The transmural dispersion of 
repolarisation, that is the extent of difference between the maximal and minimal duration of 
repolarisation throughout the cardiac wall (Sicouri et al., 2010), has also been shown to be 
increased in SQTS as differences in ionic conductance across tissue layers or cell types can 
be accentuated by mutations (Elming et al., 1998, Okin et al., 2000, Bjerregaard et al., 2006, 
Hancox et al., 2018), and this further increases the susceptibility to re-entry. These re-
entrant circuits lead to the formation of spiral waves which circulate around an 
arrhythmogenic substrate and cause the atrial or ventricular fibrillation (VF) symptomatic of 
SQTS (Cerrone et al., 2006). 
In silico modelling by Harrell et al. (2015) which used their established properties of I560T-
hERG for the induction of IKr in the left ventricular wall model calculated an abbreviated QT 
interval of 287ms as compared with 388ms in their WT simulations. Application of a protocol 
modelling VF through simulation of a premature stimuli showed WT IKr to cause immediate 
termination of spiral waveforms, whereas the alteration in kinetics seen in I560T-hERG 
resulted in sustained spiral wave rotation which would be expected to cause severe VF 
clinically. The proband was never recorded as suffering VF, but the results are consistent 





simulations investigating the atrial consequences of the I560T mutation to increase 
understanding of the atrial symptoms suffered by the patient have been performed, and so 
the differences seen during my atrial AP clamp work (Figure 13A) are key for understanding 
the patient’s symptoms. The more than doubling of IhERG caused by the I560T mutation will 
certainly drive repolarisation and facilitate circuit re-entry in the atria in addition to the 
ventricles. Further modelling must be done using atrial conditions to increase understanding 
of the effects of the I560T mutation, and in addition to this, the more detailed properties of 
IhERG found by my work should be applied to ventricular in silico modelling to demonstrate 
further the arrhythmogenic properties of the mutation.  
Previous comparable work on N588K-hERG showed the mutation to augment the difference 
in peak current between the waveforms of different tissue types significantly. Whilst WT 
ventricular IhERG was 2.9-fold greater than that of atrial IhERG and 1.7-fold greater than that of 
PF IhERG, the N588K mutation augmented ventricular IhERG to 6.6-fold that of atrial and 2.6-
fold that of WT, showing the mutation to affect current during each waveform to differing 
extents, contributing to the development of heterogeneity during repolarisation (McPate et 
al., 2009a). This work, however, has shown that the more modest nature of the I560T 
mutation causes total IhERG to be augmented to a similar extent across all waveforms (Figure 
14), and so the aforementioned in silico work will be also useful in understanding the 
differences in arrhythmogenesis between a mutation which severely attenuates inactivation 
and this more modest mutation. 
 
3.4.4 Response of I560T-hERG to quinidine and sotalol 
This study is the first to investigate the effects of the I560T mutation on sensitivity of IhERG to 
antiarrhythmic drugs. Quinidine and sotalol were chosen due to their known IKr blocking 
properties and prior use in the treatment of SQT1 (Wolpert et al., 2005, McPate et al., 2008, 





properties of both drugs and so they make an excellent comparative tool for probing the way 
in which the I560T mutation affects key mechanisms of drug binding to hERG.  
Site directed mutagenesis work on a range of structurally diverse drugs has highlighted two 
residues, Y652 and F656 (see Figure 19), to be consistently vital for high affinity drug 
binding (Mitcheson et al., 2000, Perry et al., 2004, Kamiya et al., 2006, Duan et al., 2007, Jo 
et al., 2008, Zhang et al., 2016), and separate studies showed mutation of these residues to 
reduce quinidine potency by at least 30-fold (Lees-Miller et al., 2000a, Sanchez-Chapula et 
al., 2003). These sites lie within the S6 helix which lines the K+ conduction pathway and so 
drug binding is proposed to occur commonly below the selectivity filter (Helliwell et al., 
2018). For some drugs, including methanesulphonanilide class III antiarrhythmics such as 
sotalol, inactivation gating has also been shown as a key in stabilising drug binding, and this 
has been demonstrated using mutations shown to attenuate inactivation (Lees-Miller et al., 
2000a, Ficker et al., 2001, McPate et al., 2008, Perrin et al., 2008, Du et al., 2014, Zhang et 
al., 2016, Helliwell et al., 2018). This occurs as the process of inactivation gating is believed 
to involve rotation of the S6 helices, and this leaves key residues facing into a more 
 
Figure 19: Pore region of the hERG channel with key drug binding residues highlighted on each 
protein. Discussed residues associated with SQTS are also shown. Construct built using the recent 
cryo-EM structure (Wang and MacKinnon, 2017) and provided by Dr Christopher Dempsey 





favourable direction for binding to certain drugs (Chen et al., 2002, Helliwell et al., 2018). 
Consequently, perturbations to inactivation affect drugs to varying extents, with studies 
showing the IC50 of quinidine to increase only 3.5-5.8-fold in response to the S631A or 
N588K mutations (Lees-Miller et al., 2000a, Wolpert et al., 2005, McPate et al., 2008). These 
known properties of quinidine agree well with my finding of a modest, 2.3-fold increase in 
IC50 caused by the I560T mutation’s moderate effects on inactivation (Figure 15).  
A recent study also highlighted the importance of the S5 residue F557 (see Figure 19) in 
drug binding (Saxena et al., 2016). A range of structurally diverse hERG blockers (not 
including quinidine) were applied, showing the mutation of F557 to have an effect 
comparable to that of Y652 mutations. This is interesting in the case of the I560T mutation 
due to the aforementioned potential for threonine-induced bending of the S5 helix (see 
Section 3.4.2). If this bending is occurring then it will involve T560 bonding either with F557 
itself or the adjacent T556, which is likely to affect the positioning and availability of F557 
through either direct or allosteric modulation. Consequently, it is feasible that both this 
mechanism and the reduced inactivation gating have a modest effect on binding which both 
contribute to the increased IC50 of quinidine.  
The N588K mutation causes a larger shift in the IC50 of quinidine during patch-clamp 
experiments than does the I560T mutation, with a reported IC50 of 3.5-4.35µM (Wolpert et 
al., 2005, McPate et al., 2008). Despite this being higher than the mean serum concentration 
measured in patients during a standard regime involving an oral quinidine dosage of 
1000mg/day (~2.9µM; Schimpf et al., 2007), the drug still retains effectiveness clinically 
(Wolpert et al., 2005, Giustetto et al., 2015). N588K patients receiving oral administration of 
quinidine show a prolongation of the QT interval and of the ERP as a result of treatment; and 
dosage also rendered VF non-inducible for patients in whom it had been inducible (Gaita et 
al., 2004, Giustetto et al., 2006, Giustetto et al., 2015). As the IC50 of quinidine for I560T-





it is more than likely that the increased IC50 caused by the mutation is not sufficient to disrupt 
quinidine’s therapeutic properties. 
In prior work, sotalol binding has been shown as highly dependent upon inactivation gating, 
with attenuation of this causing a 20-fold increase in IC50 (Brugada et al., 2004).  
Consequently, it was anticipated that the attenuation in inactivation caused by the I560T 
mutation would lead to a larger reduction in affinity for sotalol than quinidine, possibly akin to 
the T618I mutation which caused a +25mV shift in inactivation associated with a 3.2-fold 
increase in IC50 of sotalol and only a 1.4-fold increase in IC50 of quinidine using comparable 
experiments (El Harchi et al., 2012). This however, was a contrast to the results produced, 
with the I560T mutation causing no change in binding to sotalol (Figure 16). The reasoning 
behind these differences is unclear. The more modest effect of the I560T mutation on 
inactivation compared with other mutations used in study of sotalol (Numaguchi et al., 2000, 
Brugada et al., 2004, Perrin et al., 2008) likely contributes to the reduced effect on binding, 
and the differences between T618I and I560T-hERG may be attributed to the more distal 
location of the mutation compared to the channel pore.  
In vitro, sotalol was also shown as an effective hERG blocker and a strong candidate for use 
in patients with the T618I mutation, with no more than a 1.7-fold increase in IC50 caused by 
the mutation under AP clamp conditions (Sun et al., 2011, El Harchi et al., 2012). However 
subsequent in vivo work has shown sotalol not to prolong the QTc interval or to reduce 
susceptibility to ventricular arrhythmias (Giustetto et al., 2015, Hu et al., 2017). Although 
quinidine also failed to prevent arrhythmias in some T618I cases, it was successful in 
prolonging QT interval and has in general been seen as the most effective treatment for 
SQT1 (Giustetto et al., 2015, Hu et al., 2017, Hancox et al., 2018). Despite my work showing 
I560T to have a lesser effect on sotalol binding compared to that of quinidine, I believe that 
suggesting quinidine supplementation for the identified I560T patient would be more 
appropriate due to a combination of the retained effectiveness of the drug in N588K patients 





al., 2006, Giustetto et al., 2015). The limited availability of quinidine in many countries, 
however, means that it may not be a possible therapeutic option, with one 2013 study 
showing it only as ‘readily available’ in 14% of countries (Viskin et al., 2013b, Mazzanti et al., 




The I560T mutation produces a range of effects on hERG properties, with the increase in 
current density and the positive shift in the voltage dependence of inactivation being the 
most consequential. These changes are expected to increase IKr during cardiac action 
potentials and shift the timing of the current during the during the PF and ventricular APs 
which elicit the highest levels of IhERG. As a result, AP repolarisation and therefore QT 
interval and the ERP will be accelerated, increasing susceptibility to arrhythmia. Despite the 
alteration to IhERG kinetics, there is relatively little change in the binding properties of 
quinidine and no change in the affinity of sotalol. While both may offer an effective 
therapeutic option, the clinical history of quinidine usage suggests it may be of most value in 







Chapter 4     Effects of the S631A hERG mutation in the context of 
SQTS 
4.1 Introduction 
The use of the S631A hERG mutation within the laboratory predates the identification of 
SQTS as a clinical entity, with the first work published in 1996 (Schonherr and Heinemann, 
1996). S631 in hERG corresponds to a pore residue (T449) which was previously shown to 
be critical for inactivation in Shaker B channels (Lopez-Barneo et al., 1993); and in the non-
inactivating rat and drosophila EAG channels an alanine rather than serine is present at 
position 631 (Warmke et al., 1991, Ludwig et al., 1994). Consequently, Schonherr and 
Heinemann (1996) created the S631A mutation to investigate its effects on hERG channel 
gating, showing the mutation to eliminate inactivation under their conditions. Subsequent 
work has shown that inactivation is not removed, but is markedly positively shifted, resulting 
in a reduction in current rectification at positive voltages (Hancox et al., 1998b, Zou et al., 
1998, Fan et al., 1999, McPate et al., 2008). The mutation has also been shown to have no 
significant effect channel activation (Schonherr and Heinemann, 1996, Zou et al., 1998, Fan 
et al., 1999, McPate et al., 2008) or ion selectivity (Fan et al., 1999) and its use has helped 
to demonstrate the critical role of hERG inactivation during the ventricular AP (Hancox et al., 
1998b). Furthermore, a number of pharmacological studies have used the mutation to 
investigate the effects of the attenuation of inactivation on drug binding (Lees-Miller et al., 
2000a, Paul et al., 2001, Weerapura et al., 2002a, McPate et al., 2008). 
The identification of a patient expressing S631A-hERG, over 20 years after the initial study 
of the mutation, represented the first observation of an SQTS mutation with an effect on 
inactivation as profound as that seen for the N588K mutation (McPate et al., 2005, Akdis et 
al., 2017, Hancox et al., 2018). A female proband, who’s most recent QTc interval was 
323ms, had a father and sister who presented with QTc intervals of 324ms and 340ms 
respectively; and an aunt and two cousins died suddenly of unreported causes. Although the 





lack of further symptoms resulted in no treatment being received by the family members, 
whilst the proband herself received an ICD which has not triggered since implantation (Akdis 
et al., 2017).  
Some existing hERG literature describes the comparable nature of the effects of the N588K 
and S631A mutations, with similarities being drawn between the mutations’ effects on the 
voltage dependence of activation and inactivation as well as upon retention of drug binding 
(Schonherr and Heinemann, 1996, Zou et al., 1998, Fan et al., 1999, Paul et al., 2001, 
Cordeiro et al., 2005, McPate et al., 2005, McPate et al., 2008). Now that the mutation has 
been identified clinically, the aim of the study comprising this chapter was to supplement the 
current literature and provide data on how the S631A mutation affects IhERG during APs from 
different cardiac regions. It is predicted that further similarities with N588K may be found, 
with previous work showing profound differences between WT and N588K IhERG profiles 
during cardiac APs (Brugada et al., 2004, Cordeiro et al., 2005, McPate et al., 2009a). As 
drug binding can vary between the square voltage command protocols and physiological 
waveforms (Kirsch et al., 2004, Yao et al., 2005, Milnes et al., 2010, El Harchi et al., 2012), 
this work also aims to use quinidine during AP clamp in order to supplement the current 
literature and investigate the notion from previous work that quinidine is likely to be an 
effective adjunctive therapy for patients with the S631A mutation. In contrast to the I560T 
mutation, conventional voltage clamp has been widely used in previous studies to 
characterise S631A-hERG kinetics (Schonherr and Heinemann, 1996, Hancox et al., 1998b, 
Zou et al., 1998, Fan et al., 1999, McPate et al., 2008), and so the use of AP clamp here 






4.2.1 Physiological consequences of the S631A mutation 
4.2.1.1 Effects of the S631A mutation on I-V relations 
As described above, conventional voltage clamp has been previously used to characterise 
the S631A mutation (Schonherr and Heinemann, 1996, Hancox et al., 1998b, Zou et al., 
1998, Fan et al., 1999, McPate et al., 2008), and so the majority of this section focusses 
upon the novel use of AP clamp with conventional voltage clamp used only to establish I-V 
relations of WT and S631A channels. This is important to ensure the reported properties of 
S631A-hERG are reflected under the current laboratory conditions and has been done using 
the protocols shown in the lower panels of Figure 20A and 20B. From a holding potential of -
80mV, a 2 second depolarising command was applied, followed by a 4 second repolarising 
command to -40mV (as in Chapter 3, Figure 6). For WT IhERG, depolarising commands 
increased by 10mV from -40 to 60mV. Due to the large attenuation of inactivation caused by 
the S631A mutation (Schonherr and Heinemann, 1996, Hancox et al., 1998b, Zou et al., 
1998), this protocol was modified to include voltages up to 100mV in order to capture fully 
the positively shifted IhERG rectification, as has previously been shown effective for the 
comparable N588K mutation (Cordeiro et al., 2005, McPate et al., 2005). Additionally, 20mV 
steps were used over this wider voltage range for S631A to increase the likelihood of 
maintaining cell integrity throughout the duration of the protocol (McPate et al., 2005). 
As can be seen in Figure 20C WT IhERG exhibited the expected I-V relations as previously 
demonstrated in Figure 6Ai and 6B. Through decreasingly negative membrane potentials 
IhERG rose and peaked at 0-10mV. Subsequently, inactivation became more dominant and 
IhERG rectification occurred across the range of positive membrane potentials. As a 
consequence, using a repolarisation  voltage of -40mV removed channel inactivation, and 
archetypal IhERG tail currents were evident following repolarisation from the positive 
membrane potentials (Figure 20A) (Sanguinetti et al., 1995, Schonherr and Heinemann, 





Heinemann, 1996, Hancox et al., 1998b, McPate et al., 2008), S631A IhERG continued to 
increase throughout positive test potentials and only began to decrease as the membrane 
potential reached 40-60mV (Figure 20C). S631A tail currents were also smaller than those 
elicited by the test pulse at all positive voltages (Figure 20B).  
By plotting normalised IhERG tails against the voltage at which they were elicited and fitting 
with Equation 1, the voltage dependence of activation was quantified (Figure 20D). The 
S631A mutation caused no significant change in the half maximal voltage of activation (-14.4 
± 1.8mV for S631A vs. -16.8 ± 3.0mV for the WT; n=5 vs. n=7; p>0.05) and there was also 
no change in k value (5.3 ± 1.0 for S631A vs. 8.0 ± 1.5 for WT; p>0.05). Overall, these data 
 


































































































































Figure 20: I-V relationship for WT and S631A-hERG. Representative current traces for WT (A) and 
S631A-hERG. (B) hERG channels elicited by the protocol shown below, with only selected traces 
shown for clarity. (C) Mean I-V relations for end pulse WT and S631A IhERG. Current was normalised 
to current recorded at 0mV. (D) Mean normalized tail current I-V relations. Currents were normalized to 
the peak current recorded during the protocol for each cell and fitted by Equation 1. In (C, D) for WT 





are in agreement with previous conclusions regarding the S631A mutation and show it to 
have no effect on the voltage dependence of IhERG activation but to cause shifted rectification 
of IhERG across a positive voltage range (Schonherr and Heinemann, 1996, Zou et al., 1998, 
McPate et al., 2008). This is indicative of the known property of attenuated inactivation 
possessed by S631A-hERG, and as the data presented here are consistent with those which 
have been reported previously, the remainder of S631A experiments focus solely on the 
novel use of AP clamp to characterise better the mutation’s effects on IhERG during 
physiological waveforms. 
4.2.1.2 Effects of the S631A mutation on IhERG profile during ventricular AP 
As shown in Section 3.2.2 (Figure 12Ai), during the initial depolarising upstroke of the 
ventricular AP and the early stages of repolarisation WT IhERG was limited by channel 
inactivation, but increased progressively towards the end of the plateau phase and then 
peaked during phase 3 of the action potential (Figure 21Ai). The attenuation of inactivation, 
however, caused S631A IhERG to increase more rapidly throughout the early stages of 
repolarisation and produce a dome-shaped profile which reached its peak much earlier in the 
AP (Figure 21Aii). By plotting instantaneous I-V relations during AP repolarisation (Figure 
21B), the voltage at which each channel exhibited peak IhERG was identified. The S631A 
mutation caused a significant positive shift in this of over 50mV (-32.2 ± 2.3mV for WT vs. 
21.5 ± 2.6mV for S631A; n=6 vs. n=7; p<0.0001), demonstrating that it can be expected to 
alter significantly the profile and timing of IhERG during a ventricular AP. As above (Figure 
12Ci), conductance-voltage relations increased progressively throughout repolarisation for 
WT IhERG, peaking between _50mV and -80mV before dropping rapidly as the holding 
potential of -80mV was re-established (Figure 21Ci). S631A G-V relations however show a 
much-augmented profile, as conductance rose abruptly early during repolarisation, then 
reached a plateau for the majority of the action potential (Figure 21Cii). Thus, S631A hERG 








Figure 21: WT and S631A-IhERG response to a ventricular AP. (A) Representative traces of WT and 
S631A-IhERG profile (shown in black) during a ventricular AP (shown in grey). Current was normalised 
to capacitance reflecting cell membrane surface area. (B) Representative I-V relations recorded 
during repolarisation in a ventricular action potential. Current was normalised to the maximal current 
recorded during the protocol for each cell (C) Representative G-V relations recorded during 
repolarisation in a ventricular AP. For (B, C) the arrows represent the direction of repolarisation. For 
WT figures, representative traces were selected from a total of 6 experiments. For S631A figures, 
representative traces were selected from a total of 7 experiments. 























































































































































































4.2.1.3 Effects of the S631A mutation on IhERG profile during atrial and Purkinje fibre AP 
As established in Chapter 3 (Figure 13Ai), due to the less positive peak and more negative 
plateau phase, WT IhERG was much smaller during atrial AP than during ventricular AP, with 
reduced involvement of inactivation giving a dome-shaped IhERG profile which peaked during 
phase 3 of the AP (Figure 22Ai). Similarly, during the atrial AP, S631A IhERG produced a 
dome-shaped profile, but with the peak occurring earlier during the plateau phase (Figure 
22Aii). The lower plateau phase causes WT IhERG to be more evenly distributed throughout 
repolarisation, with a much flatter peak between -20mV and -40mV (Figure 22Bi). In contrast 
S631A IhERG increased more abruptly, peaking at a less negative voltage (-25.7 ± 3.0mV for 
WT vs. -13.8 ± 0.7mV for S631A; n=6 vs. n=6; p<0.01) and subsequently declining in a more 
linear fashion (Figure 22B). 
The WT IhERG profile in response to Purkinje fibre AP again showed signs of inactivation 
during the plateau phase, with peak IhERG occurring in phase three of the AP (Figure 22Ci). 
Similar to the atrial and in particular ventricular S631A IhERG profile, S631A IhERG rose rapidly 
following the initial AP upstroke of the PF AP, presenting a dome-like profile (Figure 22Cii); 
and also peaked earlier during repolarisation, with maximal IhERG being positively shifted by 
~35mV (-38.1 ± 2.0mV for WT vs. -3.9 ± 1.8mV for S631A; n=6 vs. n=6; p<0.0001; Figure 
22D). Figure 23A and 23B show comparison of maximal IhERG current (normalised to 
capacitance reflecting cell membrane surface area) between the different cardiac AP 
waveforms. This highlights that augmentation of peak IhERG occurred proportionately across 







Figure 22: WT and S631A-IhERG response to atrial and Purkinje fibre APs. (A) Representative profiles 
of WT (i) and S631A (ii) IhERG during an atrial AP. (B) Representative I-V relations recorded during 
repolarisation in an atrial AP for WT (i) and S631A (ii) cells. (C) Representative profile of WT (i) and 
S631A (ii) IhERG during Purkinje fibre AP. (D) Representative I-V relations during Purkinje fibre AP. 
For (A, C) the current traces (black) overlay the protocol used (grey) and current was normalised to 
capacitance reflecting cell membrane surface area. For (B, D) the arrows represent the direction of 
repolarisation and current was normalised to the maximal current recorded during the protocol for 
each cell. For all waveforms and both WT and S631A figures, representative traces were selected 
from 6 experiments. 













































































































































































































































































































Figure 23: Comparison of WT and S631A-IhERG density and timing during ventricular, atrial and PF 
APs. (A) Peak WT-IhERG density during ventricular, atrial and PF APs, with current normalised to 
capacitance reflecting cell membrane surface area. (B) Peak S631A-IhERG density during ventricular, 
atrial and PF APs, with current normalised to capacitance reflecting cell membrane surface area. (C) 
Mean voltage at which peak repolarising IhERG occurred during each AP waveform. For all WT 
experiments n=6; for ventricular S631A experiments n=7; for PF and atrial S631A experiments n=6.  
 
4.2.2 Response of S631A-hERG to quinidine 
Previous work using voltage clamp has shown the attenuation of inactivation to have only a 
modest effect on IhERG blockage by quinidine (Lees-Miller et al., 2000a, McPate et al., 2006, 
McPate et al., 2009a), however it is known that variation in drug potency can occur between 

































































































El Harchi et al., 2012). Consequently, using AP clamp to investigate the effects of quinidine 
on WT and, for the first time, S631A IhERG will work towards an increased understanding of 
the mutation and potential therapeutic strategies. Following on from the results shown in 
Section 3.2.3.1 and in line with other published data (Paul et al., 2002, McPate et al., 2008, 
El Harchi et al., 2012), a concentration of 1μM quinidine was selected to partially block IhERG 
during a ventricular action potential. 
Figure 24A shows representative traces for WT and S631A IhERG in response to a ventricular 
AP in the absence (black) or presence (grey) of 1μM quinidine, with a reduction in IhERG 
magnitude throughout the AP following the application of quinidine visible for both channels. 
This has been quantified in Figure 24B, where the reduction in peak repolarising current (Bi) 
and inhibition of total current integral (Bii) have been calculated. Figure 24Bi shows the 
fractional block of maximal IhERG was decreased from 71.9 ± 3.5% in the WT to 57.1 ± 5.1% 
for S631A-hERG (n=5 vs. n=6; p<0.05), whereas Figure 24Bii shows that the reduction in 
total charge carried throughout the AP was not significantly different for the mutated 
channels (74.0 ± 2.4% for WT vs. 63.0 ± 6.2% for S631A; n=5 vs. n=6; p>0.05). Taken 
together, these results show that under AP clamp, the S631A mutation only modestly affects 








Figure 24:  Inhibition of WT and S631A-IhERG by quinidine. (A) Representative traces of WT (i) and 
S631A (ii) IhERG in the absence (black) and presence (grey) of 1μM quinidine during a ventricular AP. 
(Bi) Reduction in maximal IhERG recorded during the AP following the application of 1 μM quinidine. 
(Bii) Reduction in current integral following the application of 1μM quinidine. A minimum of 5 cells 
were used for each concentration of drug. For WT experiments n=5; for S631A experiments n=6. 





































































































































4.3 Summary of S631A data 
Property WT S631A Significance 
IhERG properties during voltage clamp 
V0.5 (activation) (mV) 16.8 ± 3.0 (n=7) -14.4 ± 1.8 (n=5) p>0.05 
k (activation, mV) 8.0 ± 1.5 (n=7) 5.3 ± 1.0 (n=5) p>0.05 
Voltage of maximal IhERG during AP clamp 
Ventricular AP (mV) -32.2 ± 2.3 (n=6) 21.5 ± 2.6 (n=7) p<0.0001 
Atrial AP (mV) -25.7 ± 3.0 (n=6) -13.8 ± 0.7 (n=6) p<0.01 
Purkinje fibre AP (mV) -38.1 ± 2.0 (n=6) -3.9 ± 1.8 (n=6) p<0.0001 
Response to quinidine 
Reduction in maximal IhERG (%) 71.9 ± 3.5 (n=6) 57.1 ± 5.1 (n=6) p<0.05 
Reduction in current integral (%) 74.0 ± 2.4 (n=6) 63.0 ± 6.2 (n=6) p>0.05 








4.4.1 Physiological consequences of the S631A mutation 
In line with previous studies, the I-V relations demonstrated in Figure 20 show that the 
S631A mutation caused no change in the voltage dependence of activation but positively 
shifted IhERG rectification (Schonherr and Heinemann, 1996, Zou et al., 1998, Fan et al., 
1999, McPate et al., 2008). Previous comparable work has shown the S631A mutation to 
cause a ~90mV shift in the inactivation V0.5 (McPate et al., 2008), and this is the underlying 
basis for the ~40mV shift in current rectification compared with WT channels. As a 
consequence of this shift it could be predicted that very little inactivation would occur during 
the AP clamp commands, as during each physiological waveform the plateau phase occurs 
at a voltage less positive than the range of current rectification, and only during the 
ventricular AP does the membrane potential reach a voltage likely to cause significant 
inactivation. Thus, over the vast majority of physiologically relevant voltages, channel 
inactivation can be considered essentially to be removed. This is evident in Figure 21A, 21A 
and 21C where a dome-shaped S631A-IhERG profile was produced in response to ventricular, 
atrial and PF APs, whereas under WT conditions the limiting of current by inactivation was 
clearly evident during the ventricular and PF AP. Quantifying this augmentation by plotting 
the instantaneous I-V relations (Figure 21B, 22B and 22D) shows a positive shift in peak 
IhERG during each AP, corresponding to maximal current occurring earlier in the AP and 
consequently abbreviating repolarisation (Figure 23C).  
In each case, this shift produced by the mutation is greater than that caused by the I560T 
mutation and highly comparable to that caused by the N588K mutation. The S631A mutation 
caused a positive shift of ~50mv, ~10mV and ~35mV during ventricular, atrial and PF APs 
respectively, whereas previous work using similar conditions showed the N588K mutation to 
augment peak IhERG by ~60mV, ~15mV and ~30mV respectively, also showing a dome-
shaped profile (McPate et al., 2005, McPate et al., 2009a). This is in agreement with voltage 





105mV, similar to the ~90-100mV shifts reported for S631A (Zou et al., 1998, Cordeiro et al., 
2005, McPate et al., 2005, McPate et al., 2008), whilst also having no effect on the voltage 
dependence of activation. Such similarities make it possible to take findings associated with 
the N588K mutation and predict that the results may be similar in the context of the S631A 
mutation (Hancox and Stuart, 2018). For example, prior in silico study of the N588K mutation 
has shown that the mutation increases IKr ~5-fold (Adeniran et al., 2011). My own work was 
limited by the necessity of using different concentrations of DNA for transfection of each 
construct, and this prevented a direct comparison of IhERG magnitude. The N588K-based in 
silico work however suggest that a similar increase in IKr may be caused by the S631A 
mutation. As described above, an increase in IhERG amplitude will drive repolarisation and QT 
interval shortening, and in the case of the N588K mutation, this was shown to predispose to 
the uni-directional conduction block which facilitates re-entrant arrhythmia (Adeniran et al., 
2011). An increase in local electrical heterogeneity and a reduction in the substrate size 
required to maintain spiral waves was also shown to be caused by the mutation, further 
highlighting ways in which the S631A may contribute to ventricular arrhythmogenesis 
(Adeniran et al., 2011). 
At present, the S631A mutation has not been associated clinically with any supraventricular 
arrhythmia (Akdis et al., 2017), however SQTS is typically characterised by atrial in addition 
to ventricular arrhythmia (Maury et al., 2008, Rudic et al., 2014, Chen et al., 2016, Hancox et 
al., 2018), and atrial consequences have been identified in SQT1 patients with the I560T and 
T618I mutations as well as with the N588K mutation (Brugada et al., 2004, Giustetto et al., 
2015, Harrell et al., 2015). Given the small sample size of S631A patients, it would be naïve 
to rule out the potential for S631A-induced atrial arrhythmia and this is supported by the data 
presented in Figure 22. As seen during the ventricular AP, the earlier timing of IhERG during 
an atrial AP will abbreviate repolarisation and would be expected to facilitate re-entry by 
reducing the ERP (Adeniran et al., 2011, Rudic et al., 2014, Hancox et al., 2018). Atrial 





timing caused by the N588K mutation to increase propensity for AF (Loewe et al., 2014), and 
so it is feasible that this could also be experienced by the S631A patients, although further 
clinical investigations would need to be performed to confirm this.  
As highlighted in Figure 23C, during each AP waveform IhERG timing was shifted to differing 
extents, and consequently the S631A mutation contributes to heterogeneity across the 
various cardiac tissues. As described above, this amplified heterogeneity further increases 
the susceptibility to arrhythmia (McPate et al., 2009a, Adeniran et al., 2011), however, as 
with the I560T mutation, further in silico work must be done in order to characterise fully the 
S631A mutation to understand better its effects in different tissue types. 
 
4.4.2 Molecular context of the S631A mutation 
As shown in Figure 25, the S631A residue is located outside the selectivity filter and within 
the outer residues of the pore helix (Wang and MacKinnon, 2017). As described in Section 
4.1, the mutation was originally induced with the aim of attenuating inactivation, and 
consequently the mechanisms by which this occurs are much clearer than those of I560T 
(Schonherr and Heinemann, 1996, Hancox et al., 1998b). Following the initial S631A 
studies, the critical nature of the S631A residue in rapid inactivation was reinforced by work 
showing that, in the homologous, non-inactivating EAG, mutation of residues equivalent to 
hERG 631 and 620 to serine was sufficient to recapitulate hERG’s rapid inactivation (Ficker 
et al., 2001) and a number of different mutations to the S631 residue attenuate inactivation 
(Fan et al., 1999). Interestingly, other mutations to the residue (S631V, S631K and S631E) 
which disrupted inactivation to a larger extent were also shown to shift the voltage 
dependence of activation of the channel, although the mechanisms underlying this are 





The highly comparable nature of the S631A and N588K mutations is of particularly interest 
due to the spatial difference between the two residues. Unlike S631, N588 lies within the S5-
P linker (Figure 25) (Liu et al., 2002, Brugada et al., 2004, Wang and MacKinnon, 2017). 
Mutations to a number of residues within the S5-P linker have been shown to attenuate 
inactivation (Liu et al., 2002, Vandenberg et al., 2004, Clarke et al., 2006), possibly due to 
perturbations to the linker’s ability to interact with both the channel pore and the voltage 
sensing domain (Liu et al., 2002, Clarke et al., 2006), and so N588K represents a clinically 
relevant mechanism for attenuated inactivation distinct from that of S631A. This difference in 
location is key in the study of pharmacological agents as it means that similarities in 
alterations to dug binding between the two mutations are caused by a disturbance of the 
inactivation process, whereas any differences are likely related to more localised changes. 
With this in mind, studies have shown that binding of drugs with a variety of structures 
including dofetilide, flecainide, disopyramide, quinidine, propafenone and amiodarone are 
similarly affected by the two mutations (McPate et al., 2008, Perrin et al., 2008, Melgari et 
 
Figure 25:  Structural context of the S631 residue. S631 lies above the selectivity filter (SF; shown 
in orange) and within the outer residues of the pore helix. The N588K residue (S5-P linker) is also 
highlighted, as are the key drug binding residues Y652 and F656 which sit below the SF. Construct 
built using the cryo-EM structure (Wang and MacKinnon, 2017) and provided by Dr Christopher 





al., 2015) thus highlighting the process of inactivation to be of varying importance for drug 
binding, but this to be irrespective of the specific mutations to the N588 and S631. This has 
been supported by site-directed mutagenesis which simultaneously relocated the key drug 
binding residues Y652 and F656 (shown in Figure 25) along the S6 helices and attenuated 
inactivation and showed that S6 helices rotate during inactivation gating, facing the residues 
into a state compatible with high affinity drug binding (Chen et al., 2002). Consequently, it is 
believed that it is this rotation rather than inactivation as such which is key for drug binding 
(Chen et al., 2002, Helliwell et al., 2018). This is further supported by the studies of the non-
inactivating EAG which show that although it also possesses residues homologous to Y652 
and F656, it is not susceptible to high affinity block by potent hERG inhibitors (Ficker et al., 
1998, Herzberg et al., 1998).  
As a result of my work and prior studies it can be predicted with confidence that in vivo the 
S631A mutation will result in a reduced the effect of a number of drugs. As described in 
Section 3.4.4 however, the reduction in affinity for quinidine caused by the N588K mutation 
was not large enough prevent it from being useful clinically and the drug has consistently 
been used in the treatment of SQT1. Prior studies using traditional, square-pulse voltage 
clamp have shown the S631A mutation to cause a 1.25-3.5-fold (Lees-Miller et al., 2000a, 
McPate et al., 2008) decrease in potency of quinidine compared to WT channels, but to my 
knowledge no previous study has investigated the how different this is under AP clamp 
conditions. The data presented in Figure 24 supports a modest change in sensitivity to 
quinidine with only a ~15% reduction in the fractional inhibition of peak IhERG and no 
significant change in reduction of current integral throughout the ventricular AP. The use of 
1μM quinidine in my work is notably lower that the mean serum concentration (~2.9µM) 
measured in patients (Schimpf et al., 2007), and so as with the I560T mutation, this data is 
supportive of the use of quinidine as an adjunctive agent for patients with the S631A 
mutation. As far as has been reported, none of the patients identified in the study by Akdis et 





With regard to the aforementioned reduced clinical availability of quinidine (Viskin et al., 
2013a, Mazzanti et al., 2017a), it is worth noting that in the case of N588K, disopyramide 
was shown to be a more effective hERG blocker than quinidine in vitro (McPate et al., 2006) 
and the inhibition of N588K and S631A IhERG by disopyramide was similar (Paul et al., 2001, 
McPate et al., 2008). In a small clinical study, two patients with the N588K mutation 
receiving disopyramide as an alternative to quinidine both experienced prolongation of the 
QTc interval and an increase in the effective refractory period (Schimpf et al., 2007), with 
subsequent in silico work demonstrating this QTc interval prolongation to be a result of IKr 
block whilst the increase in ERP was due to inhibition of both IKr  and INa (Whittaker et al., 
2017), and so it is feasible to recommend disopyramide as an alternative in areas where 
quinidine is unavailable. In summary, the mechanisms which link attenuated inactivation to 
changes in drug sensitivity reinforce to use of the N588K mutation as a comparable tool, and 
the available data combined with the data presented in Figure 24 make a strong case to 
support the use of quinidine as an adjunct therapy in SQT1 patients with the S631A 
mutation.  
4.5 Conclusion 
The S631A mutation has long been reported to have a profound effect on hERG channel 
gating and drug binding properties. This study’s application of AP clamp to cells expressing 
S631A-hERG has demonstrated that the attenuation of inactivation caused by the mutation 
significantly augments IhERG profile during ventricular, atrial and PF APs. This can be 
expected to abbreviate repolarisation and therefore QT interval in vivo and increase 
susceptibility to both ventricular and atrial arrhythmia. Application of quinidine blocked both 
WT and S631A IhERG to a similar extent, suggesting it may work as an effective therapeutic 
option for S631A-induced SQT1, a conclusion reinforced by previous conventional voltage 







Chapter 5    General Discussion  
5.1 Clinical relevance of findings 
Much work has been done previously using heterologous expression of hERG channels in 
mammalian cell lines. Prior work conducted using approaches similar to those adopted here 
has demonstrated an underlying electrophysiological basis for symptoms experienced by 
SQT1 patients (Brugada et al., 2004, McPate et al., 2005, Wilders and Verkerk, 2010, Sun et 
al., 2011, Zhang et al., 2011, El Harchi et al., 2012) as well as demonstrating mutation driven 
changes in affinity for drugs which have been taken forward clinically and proven effective in 
vivo (McPate et al., 2006, Schimpf et al., 2007, El Harchi et al., 2012, Giustetto et al., 2015). 
Data generated by such work has also provided a basis for in silico recapitulation of SQT1, 
helping to increase understanding of the links between QT interval abbreviation, tissue 
excitability and arrhythmogenesis (Adeniran et al., 2011, Loewe et al., 2014, Whittaker et al., 
2017). Accordingly, my findings follow a similar trend by using proven patch clamp 
techniques to determine channel properties under the conditions of the I560T and S631A 
mutation.  
Using traditional voltage clamp and square voltage command protocols, the most significant 
finding regarding the I560T mutation was that of a ~24mV shift in the half maximal voltage of 
inactivation. Despite structurally distinct locations, this is highly comparable to both the T618I 
(25mV) and L532P (32mV) mutations studied under comparable conditions, although unlike 
I560T, the T618I and L532P mutations have both also been reported to shift the half 
maximal voltage of activation (Sun et al., 2011, Zhang et al., 2011, El Harchi et al., 2012, 
Harrell et al., 2015). This attenuation of inactivation resulted in peak IhERG occurring earlier 
during ventricular repolarisation for all both mutations, with positive shifts of ~35mV (T618I) 
and ~45mV (L532P) recorded (Zhang et al., 2011, El Harchi et al., 2012). For both, this is 
more significant than the shift in IhERG caused by the I560T mutation (~18mV) recorded using 
AP clamp in my work. Despite the I560T mutation appearing to have a more modest effect 





fibrillation, which is not true for the more prevalent T618I mutation (Hassel et al., 2008, Sun 
et al., 2011, Harrell et al., 2015, Hu et al., 2017). The reason(s) for this difference are not 
currently known. However, such comparisons highlight the need for provision of data 
regarding basic channel properties, such as that presented throughout Chapters 3 and 4, 
which can be used for in silico studies to help build our understanding of how altered 
channel function can cause arrhythmia and how this differentiates between tissue types. 
This is reinforced by comparison of the S631A and N588K mutations, as the work done on 
both mutations prior to the identification of a patient harbouring the S631A mutation bore 
predictions on drug binding and IhERG profile during physiological waveforms which were 
further supported by my work (Hancox et al., 1998b, Lees-Miller et al., 2000a, McPate et al., 
2006, McPate et al., 2008, McPate et al., 2009a). 
In vitro study of SQT1 mutations is generally consistent with the alterations to QTc interval 
suffered by patients. Although no AP clamp data regarding the E50D or R1135H mutations 
are available, their reported properties mostly differ from WT channels with respect to IhERG 
amplitude and deactivation rates, with only a modest shift in inactivation also described for 
E50D (but no data published). Consequently, it can be predicted that timing of peak IhERG will 
not be altered significantly during physiological waveforms and thus a less prominent clinical 
effect will occur (Itoh et al., 2009, Hu et al., 2017). This is reflected in the QTc intervals 
recorded in patients with these mutations, with the R1135H and E50D mutations reducing 
QTc intervals to 329-379ms and 366-381ms respectively, and further supported by 
knowledge that the patient identified with the E50D mutation having no history of SCD within 
the family (Itoh et al., 2009, Redpath et al., 2009). The two mutations associated with a more 
intermediate level of inactivation attenuation (I560T and T618I) are clinically linked with a 
greater reduction in QTc interval, with the largest study of T618I patients showing a mean 
QTc interval of 313ms and the only I560T patient’s QTc interval reported at a similar 319ms 
(Harrell et al., 2015, Hu et al., 2017); whilst the N588K mutation’s almost total attenuation of 





widest analysis (Hu et al., 2017). In this respect, the S631A mutation is a relative outlier, with 
the average QTc interval of the three afflicted patients being 329ms, much higher than those 
reported for the similar N588K mutation (Akdis et al., 2017). The reasons for this are unclear, 
but a much larger number of patients with the N588K mutation have been identified, with 16 
used in the aforementioned analysis (Akdis et al., 2017, Hu et al., 2017), and so perhaps 
clarity or a change in the defined QTc interval associated with the S631A mutation will occur 
if further patients are identified.  
Despite my work being consistent with other studies in the literature with clear, translatable 
results, there are some inherent limitations that should be considered, as doing so may 
identify a number of areas in which further work may be beneficial with regards to both the 
I560T and S631A mutations and perhaps also SQT1 as a whole and wider hERG channel 
function.  The principal potential limitations of the results in this thesis are considered below, 
along with the opportunities these create for future work. 
 
5.2 SQTS patients are heterozygous  
SQTS is inherited in an autosomal dominant fashion, with successfully genotyped patients 
presenting as heterozygous for their SQTS mutations (Hu et al., 2017, Hancox et al., 2018). 
This heterozygosity means that the hERG channels in patients will be formed of heteromers 
of WT and mutant subunits, rather than the homologous channels used in this study. Despite 
this, the vast majority of studies of SQT1 mutations have used homozygous expression 
(Hancox et al., 1998b, Zou et al., 1998, Lees-Miller et al., 2000a, Brugada et al., 2004, 
Cordeiro et al., 2005, McPate et al., 2005, McPate et al., 2009a, Sun et al., 2011, El Harchi 
et al., 2012, Hu et al., 2017), with limited work being published using co-expression of WT 
and mutant channels. The data available however, does suggest heterologous channels can 
cause graded alterations to channel properties (Wu et al., 2014, Wu et al., 2015, Hu et al., 
2017). Transient co-expression of T618I and WT-hERG in HEK cells increased peak IhERG 





current (Hu et al., 2017), showing that whilst co-expression reduced the effect of the 
mutation compared to expression of T618I alone, a significant change in IhERG still occurred. 
Unfortunately, further information regarding differences in hERG kinetics or make-up of 
channels cannot be drawn from the study by Hu et al. (2017) and there is no way to 
determine the number of WT/T618I-hERG subunits which contribute to the channels that 
they studied.  
Earlier work by Wu et al. (2014), however, aimed to address issues of stoichiometry of 
inactivation mutants more precisely using concatemers of WT and mutant subunits with 
attenuated inactivation in order to establish the effects of stoichiometry on channel function. 
By expressing hERG channels containing one, two or three mutant subunits with no 
(G628C/S631C) or attenuated (S620T or S631A) inactivation, this work showed that in 
channels containing the subunits with the G628C/S631C or S620T mutation, the presence of 
a single mutated subunit in a tetramer was sufficient to disrupt channel function to the same 
extent as in a mutant homomer; and in channels with subunits possessing the S631A 
mutation the number of mutant subunits contributing to the channel had a graded effect (Wu 
et al., 2014). This grading however, is not linear and the presence of one, two, three or four 
subunits caused a positive shift in the V0.5 of inactivation by 53mV, 56mV, 68mV and 77mV 
respectively (Wu et al., 2014). From this it can be inferred that the results shown in Section 
4.2.1 will be clinically relevant during heterozygous expression, with ~70% of the attenuation 
of inactivation with homozygous expression occurring when only one or two mutant subunits 
contributed to the channel (Wu et al., 2014). In addition to this, the reduced attenuation of 
inactivation recorded in heterozygous S631A channels may account for the less abbreviated 
QTc intervals recorded in patients compared to those with the N588K mutation. If, as with 
S620T, a single mutant N588K subunit disrupts channel function to the same extent as in a 
mutant homomer, then the larger clinical effect documented can be expected, but more work 





Subsequent work using the same hERG concatemers showed that a mix of WT and mutant 
subunits can also affect drug binding, with the IC50 of cisapride and dofetilide being lower in 
heterologous channels containing subunits with the S631A mutation than in monomeric 
S631A-hERG channels (Wu et al., 2015). This means it is possible that the results presented 
in Section 4.2.2 may overestimate the in vivo effect of the mutation on drug binding, (which 
was modest, even under homozygous expression conditions). Whilst work with I560T 
concatemers or dimers has yet to be performed, my data (Figure 15B and Figure 16B) 
establish the potential maximal alterations in potency of quinidine and sotalol with this 
mutation. Collectively the evidence suggests that whilst heterozygosity can moderate the 
impact of a mutation, significant changes in channel properties still occur and so the 
mechanisms by which the I560T and S631A mutations have been shown as linked to 
arrhythmias by my work will still bear clinical relevance. Similarly, prior work with 
concatemeric channels and the modest shifts in drug potency seen here with homozygous 
mutant expression provide a rational basis for the clinical application of drugs studied in my 
experiments. 
 
5.3 In vivo formation of hERG channels  
As described in Section 1.2.1, unlike hERG 1b, hERG 1a is capable of forming functional 
monomers in humans, however native channels are likely to be formed of hERG 1a/1b 
heteromers (Phartiyal et al., 2008, Jones et al., 2014, McNally et al., 2017) and the current 
conducted by the heteromeric channel more closely resembles that of native IKr (London et 
al., 1997). Although evidence to support a physiological role of hERG 1b is relatively limited, 
at least two cases of LQTS associated with hERG 1b mutations (A8V and R25W) have been 
identified (Sale et al., 2008, Crotti et al., 2013). More recently, cardiomyocytes derived from 
human iPSCs have been studied using shRNA to knockdown hERG 1b and using 
transformation with a hERG 1a-specific PAS domain fragment which has been previously 





Jones et al., 2014). Both of these techniques shifted the IhERG profile from one consistent with 
hERG 1a/1b heteromers to one consistent with hERG 1a homomers and inhibition of hERG 
1b was also seen as proarrhythmic, thus the work showed the hERG 1b subunit as critical in 
human hERG function and consequently key in cardiac repolarization (Trudeau et al., 2011, 
Jones et al., 2014).  
Work comparing the properties of heterologous N588K-hERG 1a/1b channels against WT-
hERG 1a/1b and monomeric hERG 1a channels showed that the inclusion of N588K-hERG 
1b subunits amplified the attenuation of inactivation caused by the N588K mutation, with no 
further effects on other channel properties (McPate et al., 2009b), possibly due to the 
reduced number N-termini which have previously been shown to interact with the S4-5 linker 
and stabilise inactivation (Wang et al., 1998, El Harchi et al., 2018). The similarities between 
the extent of IhERG inactivation attenuation for hERG1a produced by N588K and S631A 
mutation make it possible to suggest that hERG1b incorporation is likely have a similar effect 
for S631A-hERG and it also cannot be ruled out that either I560T 1a/1b heteromers may 
display properties slightly different to those of the monomers used in my work; and so this 
presents a clear opportunity for further study. Despite these potential differences in 
properties, the findings of prior work in which in vitro results with hERG1a align with in vivo 
data are supportive of the clinical relevance of my study (McPate et al., 2005, McPate et al., 
2009a, El Harchi et al., 2012, Hu et al., 2017). In addition to this, drug binding assays 
comparing affinity for 1a/1b heteromers against traditional hERG 1a monomers have 
highlighted differences in affinity, with some drugs having higher affinity for monomeric 
channels, others for heteromeric channels, and these differences in IC50 being as large as 8-
fold in some cases (Abi-Gerges et al., 2011, El Harchi et al., 2018). Of note, little difference 
in the IC50 for sotalol in the presence of hERG 1b has been found and neither study evaluate 
differences in affinity for quinidine (Abi-Gerges et al., 2011, El Harchi et al., 2018). The 
impact of mutations on this has not been investigated, and so further work could also be 





In addition to the major pore-forming subunit, potential β-subunits merit some consideration. 
Although hERG and KCNE2 interact in heterologous expression systems (Abbott et al., 
1999, Mazhari et al., 2001, Anantharam and Abbott, 2005), KCNE2 is only strongly 
expressed in the Purkinje fibres and atrial pacemaker cells, and so an in vivo interaction 
within the cardiac chambers is unlikely (Pourrier et al., 2003, Lundquist et al., 2005). In 
addition to this, heterologous expression of N588K-hERG and KCNE2 showed little 
difference in IhERG profile during ventricular, atrial or PF APs when compared with expression 
of N588K-hERG alone (McPate et al., 2009a). Furthermore, it has been shown in vitro that 
hERG preferentially interacts with KCNE1 over KCNE2 and that (in addition to the well-
established role of KCNE1 in IKs) mutation to KCNE1 can cause LQTS by modifying IKr (Ohno 
et al., 2007, Um and McDonald, 2007). Although a number of studies characterise the 
effects of KCNE1 mutations on IhERG (Bianchi et al., 1999, Ohno et al., 2007, Nof et al., 2011, 
Du et al., 2013), to the best of my knowledge no work has yet been completed determining 
whether and how SQT1 mutations influence interactions with KCNE1, and so this may offer 
another interesting area of further study both in the context of the two mutations studied here 
and within the wider SQT1 setting. 
To summarize: heterozygous expression of WT and I560T/S631A mutations to mimic more 
closely the situation in SQT1 patients could lead to quantitative differences in the extent of 
alterations of particular IhERG properties, but these are unlikely to alter the fundamental 
observations regarding which processes are altered by either mutation. Incorporation of 
hERG1b into heteromeric channels could also potentially produce a quantitative difference in 
effects of inactivation attenuation and co-expression with potential accessory subunits 
(KCNE1 or KCNE2) might also modulate IhERG, though any modulation of kinetic changes 
produced by hERG mutations by these subunits is likely to be modest. Whilst limits on the 
time available for a research MSc placed further work to address these issues outside the 





explorations of the roles of these mutations in SQT1 and of the underlying residues in IhERG 
channel gating.  
 
5.4 Conclusion 
Following the recent clinical identification of the I560T and S631A hERG mutations in the 
SQTS, this study has aimed to characterise the kinetics and pharmacology of the mutant 
channels more extensively than prior work, using both conventional voltage clamp and AP 
clamp. For I560T hERG, I have identified a larger positive shift in the voltage dependence of 
inactivation alongside wider changes in channel properties than those previously reported 
(Harrell et al., 2015), which combine to produce alterations to the channels response to 
physiological waveforms, thus increasing susceptibility to arrhythmia. As could be predicted 
from the previous literature on the S631A mutation (Schonherr and Heinemann, 1996, 
Hancox et al., 1998b, Zou et al., 1998, Wu et al., 2014), a larger augmentation of IhERG profile 
during cardiac repolarisation was seen in cells expressing S631A-hERG, demonstrating its 
ability to drive repolarisation and abbreviate the QT interval. Although both mutations 
augmented IhERG to different extents and clearly have a different underlying structural basis 
for their effects, they both showed a similar retention of binding to quinidine and I560T-hERG 
additionally showed the same affinity for sotalol as WT-hERG. In summary, the work 
presented here demonstrates the underlying mechanisms of I560T-induced SQT1 and the 
consequences of both the I560T and S631A mutations during physiological waveforms. In 
addition to this, therapeutic agents likely to be effective in attenuating the increased IKr in 







The work in Chapter 4 describing the effects of the S631A hERG mutation on IhERG during 
ventricular, atrial and Purkinje fibre APs, and the channel’s response to quinidine under AP 
clamp has been recently published and can be found under: 
Butler, A., Y. Zhang, A. G. Stuart, C. E. Dempsey and J. C. Hancox (2018). "Action potential 
clamp characterization of the S631A hERG mutation associated with short QT syndrome." 
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